
    <!doctype html>
    <html lang="en">
    <head>
      <meta charset="UTF-8">
      <title>PAnno Report</title>
      <link rel="shortcut icon" href="https://raw.githubusercontent.com/premedkb/panno/main/docs/images/panno_icon.png">
      <script src="https://kit.fontawesome.com/e540049a97.js" crossorigin="anonymous"></script>
      <link rel="stylesheet" type="text/css" href="https://raw.githack.com/premedkb/panno/main/panno/assets/custom.css">
    </head>
    
    <body>
    <div class="side-nav-wrapper">
      <div class="side-nav">
        <ul class="mqc-nav collapse navbar-collapse">
        <h1>
          <a href="#">
            <img src="https://raw.githubusercontent.com/premedkb/panno/main/docs/images/panno_icon.png" alt="PAnno">
            <br class="hidden-xs">
            <small class="hidden-xs">v0.1.0</small>
          </a>
        </h1>
          <li><a href="#pgx summary" class="nav-l1"><b>&nbsp;PGx Summary</b></a></li>
          <li><a href="#toxicity" class="nav-l2">&nbsp;&nbsp;Toxicity</a></li>
          <li><a href="#dosage" class="nav-l2">&nbsp;&nbsp;Dosage</a></li>
          <li><a href="#efficacy" class="nav-l2">&nbsp;&nbsp;Efficacy</a></li>
          <li><a href="#metabolism/pk" class="nav-l2">&nbsp;&nbsp;Metabolism/PK</a></li>
          <li><a href="#dosing guideline" class="nav-l1"><b>&nbsp;Dosing Guideline</b></a></li>
          <li><a href="#diplotype detail" class="nav-l1"><b>&nbsp;Diplotype Detail</b></a></li>
          <li><a href="#pgx annotation" class="nav-l1"><b>&nbsp;PGx Annotation</b></a></li>
          <li><a href="#about" class="nav-l1"><b>&nbsp;About</b></a></li>
        </ul>
      </div>
    </div>
    
    <div class="main_page">
    

    <h1 id="page_title">
      <a href="https://github.com/PreMedKB/PAnno" target="_blank">
        <img src="https://raw.githubusercontent.com/premedkb/panno/main/docs/images/panno_logo.png" alt="PAnno">
      </a>
    </h1>
    <p class="head_lead">
      An automated Clinical Pharmacogenomics Annotation Tool to report drug responses and prescribing recommendations by parsing the germline variants.
    </p>
    <blockquote>
      <p>Sample ID: NA20509<br>Biogeographic Group: European<br>Report Time: Thu Jul 28 11:32:03 2022</p>
    </blockquote>
    

    <div class="alert alert-info-yellow">
      <b>Disclaimer:</b> The PAnno report iterates as the release version changes. In the current release, you should only use it to evaluate whether PAnno will compile and run properly on your system. All information in the report is interpreted directly from the uploaded VCF file. Users recognize that they use it at their own risk.
    </div>
    

    <h2 id="pgx summary"><b>PGx Summary</b></h2>
    <p class="main_lead">PAnno combines genotypes with PharmGKB's clinical annotations to summarise a patient's response to a specific drug across four dimensions, including <font color="#444"><b>toxicity</b></font>, <font color="#444"><b>dosage</b></font>, <font color="#444"><b>efficacy</b></font>, <font color="#444"><b>metabolism/PK</b></font>. Response levels are indicated using <font color="#8E529A"><b>decreased</b></font>, <font color="#653F92"><b>moderate</b></font> and <font color="#44308d"><b>increased</b></font>. Results with variant-specific prescribing guidance in professional clinical guidelines or FDA-approved drug label annotations will be labeled as <font color="#54A052"><b>Level A</b></font>, otherwise as <font color="#3978B1"><b>Level B</b></font>.</p>
    
<h3 id="toxicity"><i class="fa-solid fa-skull-crossbones"></i><b> Toxicity</b></h3>

    <table id="customer_table" border="1" cellspacing="0">
      <tr>
        <th bgcolor="#ffffff" width="70px"></th>
        <th><font color="#8E529A"><i class="fa-solid fa-square-caret-down"></i> Decreased</font></th>
        <th><font color="#653F92"><i class="fa-solid fa-square-minus"></i> Moderate</font></th>
        <th><font color="#44308d"><i class="fa-solid fa-square-caret-up"></i> Increased</font></th>
      </tr>
      <tr>
        <td bgcolor="#54A052"><font color="white"><b>Level A</b></font></td>
        <td>azathioprine; capecitabine; desflurane; enflurane; fluorouracil; halothane; isoflurane; mercaptopurine; methoxyflurane; rasburicase; sevoflurane; succinylcholine; tegafur</td>
        <td>phenytoin</td>
        <td>atorvastatin; citalopram; clopidogrel; efavirenz; fluvastatin; lovastatin; pravastatin; rosuvastatin; simvastatin; warfarin</td>
      </tr>
      <tr>
        <td bgcolor="#3978B1"><font color="white"><b>Level B</b></font></td>
        <td>acenocoumarol; irinotecan</td>
        <td>methotrexate</td>
        <td>hmg coa reductase inhibitors; peginterferon alfa-2b; phenprocoumon; ribavirin</td>
      </tr>
    </table>
    
<h3 id="dosage"><i class="fa-solid fa-pills"></i><b> Dosage</b></h3>

    <table id="customer_table" border="1" cellspacing="0">
      <tr>
        <th bgcolor="#ffffff" width="70px"></th>
        <th><font color="#8E529A"><i class="fa-solid fa-square-caret-down"></i> Decreased</font></th>
        <th><font color="#653F92"><i class="fa-solid fa-square-minus"></i> Moderate</font></th>
        <th><font color="#44308d"><i class="fa-solid fa-square-caret-up"></i> Increased</font></th>
      </tr>
      <tr>
        <td bgcolor="#54A052"><font color="white"><b>Level A</b></font></td>
        <td>acenocoumarol; azathioprine; phenprocoumon; tacrolimus; warfarin</td>
        <td></td>
        <td>mercaptopurine</td>
      </tr>
      <tr>
        <td bgcolor="#3978B1"><font color="white"><b>Level B</b></font></td>
        <td>carbamazepine</td>
        <td></td>
        <td>fentanyl</td>
      </tr>
    </table>
    
<h3 id="efficacy"><i class="fa-solid fa-vial-circle-check"></i><b> Efficacy</b></h3>

    <table id="customer_table" border="1" cellspacing="0">
      <tr>
        <th bgcolor="#ffffff" width="70px"></th>
        <th><font color="#8E529A"><i class="fa-solid fa-square-caret-down"></i> Decreased</font></th>
        <th><font color="#653F92"><i class="fa-solid fa-square-minus"></i> Moderate</font></th>
        <th><font color="#44308d"><i class="fa-solid fa-square-caret-up"></i> Increased</font></th>
      </tr>
      <tr>
        <td bgcolor="#54A052"><font color="white"><b>Level A</b></font></td>
        <td>boceprevir; peginterferon alfa-2a; peginterferon alfa-2b; ribavirin; telaprevir</td>
        <td>ivacaftor</td>
        <td>clopidogrel; lansoprazole; omeprazole; pantoprazole</td>
      </tr>
      <tr>
        <td bgcolor="#3978B1"><font color="white"><b>Level B</b></font></td>
        <td>Platinum compounds; erlotinib; gefitinib; interferons; methotrexate; rosuvastatin; warfarin</td>
        <td>rituximab</td>
        <td>atorvastatin; pravastatin</td>
      </tr>
    </table>
    
<h3 id="metabolism/pk"><i class="fa-solid fa-disease"></i><b> Metabolism/PK</b></h3>

    <table id="customer_table" border="1" cellspacing="0">
      <tr>
        <th bgcolor="#ffffff" width="70px"></th>
        <th><font color="#8E529A"><i class="fa-solid fa-square-caret-down"></i> Decreased</font></th>
        <th><font color="#653F92"><i class="fa-solid fa-square-minus"></i> Moderate</font></th>
        <th><font color="#44308d"><i class="fa-solid fa-square-caret-up"></i> Increased</font></th>
      </tr>
      <tr>
        <td bgcolor="#54A052"><font color="white"><b>Level A</b></font></td>
        <td>atorvastatin; tacrolimus</td>
        <td>simvastatin; simvastatin acid</td>
        <td>amitriptyline; celecoxib; citalopram; clomipramine; clopidogrel; dexlansoprazole; doxepin; efavirenz; escitalopram; flurbiprofen; fluvastatin; ibuprofen; imipramine; lansoprazole; lornoxicam; lovastatin; lovastatin acid; meloxicam; omeprazole; pantoprazole; phenytoin; piroxicam; pitavastatin; pravastatin; quetiapine; rosuvastatin; sertraline; siponimod; tenoxicam; trimipramine; voriconazole</td>
      </tr>
      <tr>
        <td bgcolor="#3978B1"><font color="white"><b>Level B</b></font></td>
        <td></td>
        <td></td>
        <td>nevirapine; rabeprazole</td>
      </tr>
    </table>
    
<h2 id="dosing guideline"><b>Dosing Guideline</b></h2>
<p class="main_lead">PAnno integrates brief annotations of genotype-based dosing recommendations after PharmGKB processing. Original PGx-based drug dosing guidelines include the <a href="http://cpicpgx.org/">Clinical Pharmacogenetics Implementation Consortium</a> (CPIC), the <a href="https://www.knmp.nl/dossiers/farmacogenetica/">Royal Dutch Association for the Advancement of Pharmacy - Pharmacogenetics Working Group</a> (DPWG), the <a href="https://cpnds.ubc.ca/">Canadian Pharmacogenomics Network for Drug Safety</a> (CPNDS), the French National Network for Pharmacogenetics (RNPGx), The Australian and New Zealand consensus guidelines (AusNZ), the Spanish Pharmacogenetics and Pharmacogenomics Society (SEFF), the Cystic Fibrosis Foundation (CFF), the American College of Rheumatology.</p>
<h3><b>lansoprazole</b></h3>
<p><font color="#444">Related Gene: CYP2C19<br>Detected Alleles: *2</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166219103 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104987 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>For CYP2C19 ultrarapid metabolizers who are undergoing H. pylori eradication therapy, use a 4-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 4-fold higher dose.</div>
<h3><b>tacrolimus</b></h3>
<p><font color="#444">Related Gene: CYP3A4<br>Detected Alleles: *1; rs4646437-GG</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166202481 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> RNPGx: </b>Testing for the CYP3A5*3 and CYP3A4*22 alleles is recommended in patients receiving a kidney, heart or lung transplant. CYP3A extensive or intermediate meatbolizers (EMs or IMs) should be given an initial dose of tacrolimus 1.5-2 times higher than that recommended for CYP3A poor metabolizers (PMs), up to a maximum dose of 0.30 mg/kg/day.</div>
<p><font color="#444">Related Gene: CYP3A5<br>Detected Alleles: *3</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166202481 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> RNPGx: </b>Testing for the CYP3A5*3 and CYP3A4*22 alleles is recommended in patients receiving a kidney, heart or lung transplant. CYP3A extensive or intermediate meatbolizers (EMs or IMs) should be given an initial dose of tacrolimus 1.5-2 times higher than that recommended for CYP3A poor metabolizers (PMs), up to a maximum dose of 0.30 mg/kg/day.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166124619 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC dosing guideline for tacrolimus recommends increasing the starting dose by 1.5 to 2 times the recommended starting dose in patients who are CYP3A5 intermediate or extensive metabolizers, though total starting dose should not exceed 0.3 mg/kg/day. Therapeutic drug monitoring should also be used to guide dose adjustments.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104983 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>Increased doses of tacrolimus are recommended for CYP3A5 heterozygous and homozygous expressors and adjusted as needed. Instructions for liver transplantation patients include genotypes of both patient and donor.</div>
<h3><b>phenytoin</b></h3>
<p><font color="#444">Related Gene: CYP2C9<br>Detected Alleles: *1</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166122806 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>Phenytoin/fosphenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele ('HLA-B*15:02-positive') due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Additionally, patients with the CYP2C9 poor metabolizer phenotype or with a CYP2C9 activity score of 1 may require reduced doses of phenytoin/fosphenytoin.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104984 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>Use the standard starting dose of phenytoin and reduce the maintenance dose based on CYP2C9 genotype; monitor response and serum concentrations and be aware of ADEs.</div>
<h3><b>imipramine</b></h3>
<p><font color="#444">Related Gene: CYP2C19<br>Detected Alleles: *2</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104999 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including imipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104954 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>CYP2C19 poor metabolizers should receive 70% of the standard dose of imipramine, or imipramine should be avoided in these patients. Patients should be monitored for the effect and side effects or the plasma concentrations of imipramine and desipramine in order to set the maintenance dose.</div>
<h3><b>trimipramine</b></h3>
<p><font color="#444">Related Gene: CYP2C19<br>Detected Alleles: *2</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166105001 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including trimipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.</div>
<h3><b>clopidogrel</b></h3>
<p><font color="#444">Related Gene: CYP2C19<br>Detected Alleles: *2</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104956 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>Avoid clopidogrel use in patients who are CYP2C19 poor metabolizers and are undergoing percutaneous coronary intervention, stroke or TIA. For CYP2C19 intermediate metabolizers who are undergoing percutaneous coronary intervention, stroke, or TIA, choose an alternative drug or double the dose to 150 mg/day (600 mg loading dose). No action is required for patients who are CYP2C19 ultra-rapid metabolizers.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104948 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline for clopidogrel recommends an alternative antiplatelet therapy for CYP2C19 poor or intermediate metabolizers (cardiovascular indications: prasugrel or ticagrelor if no contraindication; neurovascular indications: alternative P2Y12 inhibitor if clinically indicated and no contraindication.)</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166202501 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> RNPGx: </b>Testing for the main CYP2C19 deficiency alleles before instituting clopidogrel treatment is recommended (a test is essential for coronary angioplasty with stenting and based on the current state of knowledge this test is potentially useful in the other indications). For patients carrying at least one deficiency allele, the RNPGx recommends using an alternative treatment that is not a CYP2C19 substrate (eg. prasugrel, ticagrelor).</div>
<h3><b>sertraline</b></h3>
<p><font color="#444">Related Gene: CYP2C19<br>Detected Alleles: *2</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104980 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>Do not give doses exceeding 75 mg/day in patients with CYP2C19 poor metabolizer genotypes, and guide the dose by response and side effects and/or sertraline plasma concentration.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166127639 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor sertraline recommends to consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 poor metabolizers.</div>
<h3><b>citalopram</b></h3>
<p><font color="#444">Related Gene: CYP2C19<br>Detected Alleles: *2</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166127638 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline for the selective serotonin reuptake inhibitors citalopram and escitalopram recommends an alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 ultrarapid metabolizers. For CYP2C19 poor metabolizers, consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104977 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>The Dutch Pharmacogenetics Working Group Guideline for citalopram recommends for intermediate and poor metabolizers of CYP2C19 to not exceed the in the DPWG document specified daily doses.</div>
<h3><b>doxepin</b></h3>
<p><font color="#444">Related Gene: CYP2C19<br>Detected Alleles: *2</font></p>
<div class="alert alert-info-red"><a href=https://pharmgkb.org/guidelineAnnotation/PA166184529 target="_blank" style="color: #7C3A37"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>There are currently no dosing recommendations for doxepin based on CYP2C19 genotype.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166105000 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including doxepin. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.</div>
<h3><b>clomipramine</b></h3>
<p><font color="#444">Related Gene: CYP2C19<br>Detected Alleles: *2</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166105007 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including clomipramine. The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166184528 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends to avoid clomipramine in CYP2C19 ultrarapid metabolizer (UM) for Indication OBSESSIVE COMPULSIVE DISORDER or ANXIETY DISORDERS.</div>
<h3><b>amitriptyline</b></h3>
<p><font color="#444">Related Gene: CYP2C19<br>Detected Alleles: *2</font></p>
<div class="alert alert-info-red"><a href=https://pharmgkb.org/guidelineAnnotation/PA166184526 target="_blank" style="color: #7C3A37"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>There are currently no dosing recommendations for amitriptyline based on CYP2C19 genotype.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166105006 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline update for amitriptyline recommends an alternative drug for CYP2D6 ultrarapid or poor metabolizers and CYP2C19 ultrarapid, rapid or poor metabolizers. If amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers. For CYP2D6 intermediate metabolizers, a 25% dose reduction should be considered.</div>
<h3><b>omeprazole</b></h3>
<p><font color="#444">Related Gene: CYP2C19<br>Detected Alleles: *2</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166219103 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104957 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>For CYP2C19 ultrarapid metabolizers who are undergoing H. pylori eradication therapy, use a 3-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 3-fold higher dose.</div>
<h3><b>pantoprazole</b></h3>
<p><font color="#444">Related Gene: CYP2C19<br>Detected Alleles: *2</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166219103 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizer for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104958 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>For CYP2C19 ultrarapid metabolizers who are undergoing H. pylori eradication therapy, use a 5-fold higher dose. For CYP2C19 ultrarapid metabolizers with other indications, be alert to reduced effectiveness and, if necessary, use a 5-fold higher dose.</div>
<h3><b>rabeprazole</b></h3>
<p><font color="#444">Related Gene: CYP2C19<br>Detected Alleles: *2</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166220321 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline for CYP2C19 and Proton Pump Inhibitor Dosing states that inconsistent findings regarding the effect of CYP2C19 genotype on the pharmacokinetics and therapeutic response to esomeprazole and rabeprazole preclude making recommendations for these proton pump inhibitors.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104985 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>No action is needed for this gene-drug interaction.</div>
<h3><b>escitalopram</b></h3>
<p><font color="#444">Related Gene: CYP2C19<br>Detected Alleles: *2</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166127638 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline for the selective serotonin reuptake inhibitors citalopram and escitalopram recommends an alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 ultrarapid metabolizers. For CYP2C19 poor metabolizers, consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104975 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>The Dutch Pharmacogenetics Working Group Guideline for escitalopram recommends for intermediate and poor metabolizers of CYP2C19 to not exceed the in the DPWG document specified doses and for CYP2C19 ultrarapid metabolizer to avoid escitalopram.</div>
<h3><b>siponimod</b></h3>
<p><font color="#444">Related Gene: CYP2C9<br>Detected Alleles: *1</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166211021 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>The Dutch Pharmacogenetics Working Group Guideline for siponimod recommends decreasing the dose for CYP2C9 *1/*3, *2/*3 genotypes and to avoid siponimod for the CYP2C9 *3/*3 genotype.</div>
<h3><b>voriconazole</b></h3>
<p><font color="#444">Related Gene: CYP2C19<br>Detected Alleles: *2</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166257241 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> AusNZ: </b>An alternative antifungal agent should be considered instead of voriconazole in patients who are known to be CYP2C19 ultrarapid metabolizers. CYP2C19 genotyping and use of an alternative antifungal agent is also recommended in patients with subtherapeutic voriconazole serum concentrations despite two dose adjustments.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104990 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>Patients who are CYP2C19 poor metabolizers should receive 50% of the standard dose, and CYP2C19 ultrarapid metabolizers should receive a 1.5 times higher initial dose. Monitor voriconazole plasma concentrations for CYP2C19 poor, intermediate and ultrarapid metabolizers.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166161537 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC dosing guideline for voriconazole recommends selecting an alternative agent that is not dependent on CYP2C19 metabolism in adults who are CYP2C19 ultrarapid metabolizers, rapid metabolizers or poor metabolizers. In pediatric patients, an alternative agent should be used in patients who are ultrarapid metabolizers or poor metabolizers. In pediatric rapid metabolizers, therapy should be initiated at recommended standard case dosing, then therapeutic dosing monitoring should be used to titrate dose to therapeutic trough concentrations.</div>
<h3><b>rosuvastatin</b></h3>
<p><font color="#444">Related Gene: ABCG2<br>Detected Alleles: rs2231142-GG</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166262321 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines for patients who are SLCO1B1 or ABCG2 poor function phenotype. If dose >20mg needed for desired efficacy, consider combination therapy (i.e. rosuvastatin plus non-statin guideline directed medical therapy). Patients with both ABCG2 poor function and SLCO1B1 poor/decreased function should be prescribed ≤10mg as a starting dose.</div>
<p><font color="#444">Related Gene: SLCO1B1<br>Detected Alleles: rs4149056-CT</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166262321 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>Prescribe ≤20mg as a starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines for patients who are SLCO1B1 or ABCG2 poor function phenotype. If dose >20mg needed for desired efficacy, consider combination therapy (i.e. rosuvastatin plus non-statin guideline directed medical therapy). Patients with both ABCG2 poor function and SLCO1B1 poor/decreased function should be prescribed ≤10mg as a starting dose.</div>
<h3><b>fluvastatin</b></h3>
<p><font color="#444">Related Gene: CYP2C9<br>Detected Alleles: *1</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166262341 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>CYP2C9 IMs should avoid fluvastatin doses greater than 40mg while CYP2C9 PMs should avoid doses greater than 20mg.  If higher doses are required for desired efficacy, an alternative statin should be considered. Patients with SLCO1B1 poor function should also avoid fluvastatin doses greater than 40mg and and adjust doses of fluvastatin based on disease-specific guidelines. Patients with both SLCO1B1 poor function and CYP2C9 IM/PM should be prescribed an alternative statin depending on the desired potency.</div>
<p><font color="#444">Related Gene: SLCO1B1<br>Detected Alleles: rs4149056-CT</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166262341 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>CYP2C9 IMs should avoid fluvastatin doses greater than 40mg while CYP2C9 PMs should avoid doses greater than 20mg.  If higher doses are required for desired efficacy, an alternative statin should be considered. Patients with SLCO1B1 poor function should also avoid fluvastatin doses greater than 40mg and and adjust doses of fluvastatin based on disease-specific guidelines. Patients with both SLCO1B1 poor function and CYP2C9 IM/PM should be prescribed an alternative statin depending on the desired potency.</div>
<div class="alert alert-info-red"><a href=https://pharmgkb.org/guidelineAnnotation/PA166182845 target="_blank" style="color: #7C3A37"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>There are currently no recommendations for fluvastatin dosing based on SLCO1B1 genotypes.</div>
<h3><b>flurbiprofen</b></h3>
<p><font color="#444">Related Gene: CYP2C9<br>Detected Alleles: *1</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166191841 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% ofthe lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.</div>
<h3><b>lornoxicam</b></h3>
<p><font color="#444">Related Gene: CYP2C9<br>Detected Alleles: *1</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166191841 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% ofthe lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.</div>
<h3><b>tenoxicam</b></h3>
<p><font color="#444">Related Gene: CYP2C9<br>Detected Alleles: *1</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166192341 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline for tenoxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.</div>
<h3><b>piroxicam</b></h3>
<p><font color="#444">Related Gene: CYP2C9<br>Detected Alleles: *1</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166192321 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline for piroxicam recommends that CYP2C9 poor metabolizers and intermediate metabolizers with activity score of 1 should choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life. See full guideline for further details and supporting evidence.</div>
<h3><b>meloxicam</b></h3>
<p><font color="#444">Related Gene: CYP2C9<br>Detected Alleles: *1</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166192301 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline for meloxicam recommends alternative therapy for CYP2C9 poor metabolizers due to markedly prolonged half-life, and initiating therapy with 50% of the lowest recommended starting dose or choose an alternative therapy for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.</div>
<h3><b>ibuprofen</b></h3>
<p><font color="#444">Related Gene: CYP2C9<br>Detected Alleles: *1</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166191841 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% ofthe lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.</div>
<h3><b>dexlansoprazole</b></h3>
<p><font color="#444">Related Gene: CYP2C19<br>Detected Alleles: *2</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166219301 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline recommendations for dexlansoprazole are based on the similarity in its metabolism and lansoprazole and extrapolated from the first-generation PPIs. The guideline recommends to increase the starting daily dose and to monitor efficacy in CYP2C19 ultrarapid metabolizer. For CYP2C19 rapid and normal metabolizers in the treatment of H. pylori infection and erosive esophagitis increasing the dose might be considered after initiation with the standard starting daily dose. The recommendations for intermediate and poor metabolizers for chronic therapy (>12 weeks) and efficacy achieved is to consider 50% reduction in daily dose. See full guideline for further details and supporting evidence.</div>
<h3><b>celecoxib</b></h3>
<p><font color="#444">Related Gene: CYP2C9<br>Detected Alleles: *1</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166191841 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen and lornoxicam recommends initiating therapy with 25-50% ofthe lowest recommended starting dose for CYP2C9 poor metabolizers and initiating therapy with lowest recommended starting dose for CYP2C9 intermediate metabolizers with activity score of 1. See full guideline for further details and supporting evidence.</div>
<h3><b>quetiapine</b></h3>
<p><font color="#444">Related Gene: CYP3A4<br>Detected Alleles: *1</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166265421 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>Patients who are CYP3A4 poor metabolizers and being treated for depression should be given an alternative drug. Patients being treated for other indications and who are CYP3A4 poor metabolizers should be given a reduced dose of quetiapine. No action is needed for patients who are CYP3A4 intermediate metabolizers.</div>
<h3><b>efavirenz</b></h3>
<p><font color="#444">Related Gene: CYP2B6<br>Detected Alleles: rs3745274-GT</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166182603 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>Consider initiating efavirenz with a decreased dose of either 400 or 200 mg/day for patients who are CYP2B6 poor metabolizers. Consider initiating efavirenz with a decreased dose of 400 mg/day for patients who are CYP2B6 intermediate metabolizers.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166182846 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>Adjust the initial efavirenz dose for patients with the CYP2B6 PM phenotype along with the consideration of age, weight and BMI and titrate the dose to plasma concentration if needed. For patients with the *5/*6, *5/*18 or other CYP2B6 IM genotypes, determine the efavirenz plasma concentration if side effects occur and reduce the dose if needed.No action is required for patients with the *1/*5 or *5/*5 genotypes.</div>
<h3><b>pravastatin</b></h3>
<p><font color="#444">Related Gene: SLCO1B1<br>Detected Alleles: rs4149056-CT</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166262281 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>Prescribe ≤40mg as a starting dose and adjust doses of pravastatin based on disease-specific guidelines for patients with SLCO1B1 poor function phenotype. Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines for patients with SLCO1B1 decreased or possible decreased phenotype. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.</div>
<h3><b>lovastatin</b></h3>
<p><font color="#444">Related Gene: SLCO1B1<br>Detected Alleles: rs4149056-CT</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166262241 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>Prescribe an alternative statin depending on the desired potency for patients with SLCO1B1 decreased function, possible decreased function or poor function phenotype. If lovastatin therapy is warranted in patients with SLCO1B1 decreased or possible decreased phenotype, limit dose to <20mg/day.</div>
<h3><b>pitavastatin</b></h3>
<p><font color="#444">Related Gene: SLCO1B1<br>Detected Alleles: rs4149056-CT</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166262261 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>Prescribe ≤1mg as a starting dose for patients with SLCO1B1 poor function phenotype. Prescribe ≤2mg as a starting dose for patients with SLCO1B1 decreased or possible decreased phenotype. Adjust doses of pitavastatin based on disease-specific guidelines. Consider an alternative statin or combination therapy if higher doses are needed.</div>
<h3><b>warfarin</b></h3>
<p><font color="#444">Related Gene: VKORC1<br>Detected Alleles: rs9923231-CT; rs2884737-AC; rs7294-CT; rs9934438-AG; rs8050894-CG; rs2359612-AG</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166182841 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>Patients with the VKORC1 -1639 (rs9923231) AA genotype should be given 60% of the standard initial dose of warfarin. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. There are no recommendation for patients with the VKORC1 -1639 AG genotype.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166202621 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> RNPGx: </b>Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104949 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The updated guideline for pharmacogenetics-guided warfarin dosing is published by the Clinical Pharmacogenetics Implementation Consortium.  The  recommendations for dosing are for adult and pediatric patients that are specific to continental ancestry, and are based on genotypes from CYP2C9, VKORC1, CYP4F2, and rs12777823.</div>
<p><font color="#444">Related Gene: CYP2C9<br>Detected Alleles: *1</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166182842 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>Reduce warfarin dose in CYP2C9 poor and intermediate metabolizers (PM and IM) and patients with CYP2C9*1/*3, *2/*3, *2/*2 or *3/*3 genotype. 'The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see Algorithms coumarins</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166202621 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> RNPGx: </b>Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166170752 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPNDS: </b>The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of pharmacogenetic testing for variants in VKORC1 and CYP2C9 in adult and pediatric patients with an indication for warfarin. They recommend testing for the VKORC1 SNP -1639G>A (rs9923231) and the CYP2C9 alleles *2 and *3 in order to better guide warfarin dosage.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104949 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The updated guideline for pharmacogenetics-guided warfarin dosing is published by the Clinical Pharmacogenetics Implementation Consortium.  The  recommendations for dosing are for adult and pediatric patients that are specific to continental ancestry, and are based on genotypes from CYP2C9, VKORC1, CYP4F2, and rs12777823.</div>
<h3><b>phenprocoumon</b></h3>
<p><font color="#444">Related Gene: VKORC1<br>Detected Alleles: rs9923231-CT; rs9934438-AG</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104940 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>Patients with the VKORC1 -1639 (rs9923231) AA genotype is recommended to be given 50% of the standard initial dose of phenprocoumon and more frequent monitoring of INR. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. There is no recommendation for patients with the VKORC1 -1639 AG genotype.</div>
<h3><b>atorvastatin</b></h3>
<p><font color="#444">Related Gene: SLCO1B1<br>Detected Alleles: rs4149056-CT</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166182843 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>Choose an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and with ADDITIONAL SIGNIFICANT RISK FACTORS for statin-induced myopathy. For patients without additional significant risk factors for statin-induced myopathy, advise the patients to contact their doctor in the event of muscle symptoms.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166262221 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>Prescribe ≤20mg for patients with SLCO1B1 poor function phenotype and ≤40mg for patients with SLCO1B1 decreased or possible decreased phenotype as a starting dose.  Adjust doses of atorvastatin based on disease-specific guidelines.  Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose.</div>
<h3><b>simvastatin</b></h3>
<p><font color="#444">Related Gene: SLCO1B1<br>Detected Alleles: rs4149056-CT</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166202561 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> RNPGx: </b>Testing for rs4149056 before starting statin treatment, or early after treatment onset (potentially useful test) is recommended in patients with one or more risk factors described (as a function of statin type and dose, co-medications, and the pathophysiological or genetic setting). If the genotype is not known early, the RNPGx considers that a polymorphism test is potentially useful in the event of muscle toxicity in patients treated with statins, in order to rule out or confirm a genetic cause.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166105005 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>Prescribe an alternative statin depending on the desired potency for patients with SLCO1B1 decreased function, possible decreased function or poor function phenotype. If simvastatin therapy is warranted in patients with SLCO1B1 decreased or possible decreased phenotype, limit dose to <20mg/day.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166182844 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>Choose an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and consider any additional risk factors for statin-induced myopathy.  If an alternative is not an option for patients with the 521 TC genotype, avoid simvastatin doses exceeding 40 mg/day and advise the patient to contact their doctor in the event of muscle symptoms.</div>
<h3><b>hmg coa reductase inhibitors</b></h3>
<p><font color="#444">Related Gene: SLCO1B1<br>Detected Alleles: rs4149056-CT</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166202561 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> RNPGx: </b>Testing for rs4149056 before starting statin treatment, or early after treatment onset (potentially useful test) is recommended in patients with one or more risk factors described (as a function of statin type and dose, co-medications, and the pathophysiological or genetic setting). If the genotype is not known early, the RNPGx considers that a polymorphism test is potentially useful in the event of muscle toxicity in patients treated with statins, in order to rule out or confirm a genetic cause.</div>
<h3><b>mercaptopurine</b></h3>
<p><font color="#444">Related Gene: NUDT15<br>Detected Alleles: *1</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166184613 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>Select an alternative drug or reduce the initial dose of mercaptopurine for patients that are NUDT15 poor metabolizers and reduce initial dose for patients that are NUDT15 intermediate metabolizers.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104945 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>Consider an alternate agent or extreme dose reduction of mercaptopurine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.</div>
<p><font color="#444">Related Gene: TPMT<br>Detected Alleles: *1</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104945 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>Consider an alternate agent or extreme dose reduction of mercaptopurine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104952 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>Select an alternative drug or reduce the initial dose of mercaptopurine for patients that are TPMT poor metabolizers and reduce initial dose for patients that are TPMT intermediate metabolizers.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166202761 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> RNPGx: </b>The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) recommends testing for TPMT.</div>
<h3><b>peginterferon alfa-2a</b></h3>
<p><font color="#444">Related Gene: IFNL3<br>Detected Alleles: rs12979860-CT; rs8099917-GT; rs11881222-AG</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166110235 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>IFNL3 (IL28B) variation (rs12979860 CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.</div>
<h3><b>peginterferon alfa-2b</b></h3>
<p><font color="#444">Related Gene: IFNL3<br>Detected Alleles: rs12979860-CT; rs8099917-GT; rs11881222-AG</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166110235 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>IFNL3 (IL28B) variation (rs12979860 CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.</div>
<h3><b>ribavirin</b></h3>
<p><font color="#444">Related Gene: IFNL3<br>Detected Alleles: rs12979860-CT; rs8099917-GT; rs11881222-AG</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166110235 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>IFNL3 (IL28B) variation (rs12979860 CT or TT). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.</div>
<h3><b>methotrexate</b></h3>
<p><font color="#444">Related Gene: SLC19A1<br>Detected Alleles: rs1051266-CT</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166202781 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> RNPGx: </b>The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) states that methotrexate pharmacogenetic tests are potentially useful in cancer patients.</div>
<p><font color="#444">Related Gene: MTHFR<br>Detected Alleles: rs1801133-AG</font></p>
<div class="alert alert-info-red"><a href=https://pharmgkb.org/guidelineAnnotation/PA166265001 target="_blank" style="color: #7C3A37"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>There are currently no recommendations for methotrexate dosing based on MTHFR rs1801133 genotypes.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166202781 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> RNPGx: </b>The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) states that methotrexate pharmacogenetic tests are potentially useful in cancer patients.</div>
<h3><b>rasburicase</b></h3>
<p><font color="#444">Related Gene: G6PD<br>Detected Alleles: B (wildtype)</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166119846 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>Rasburicase is contraindicated in G6PD deficient patients with or without chronic non-spherocytic hemolytic anemia (CNSHA). In patients with a negative or inconclusive genetic test result an enzyme activity test is recommended prior to rasburicase treatment to determine whether a patient is G6PD deficient. The G6PD gene is X-linked and therefore males only have one copy, whereas females have two copies. See full guideline for disclaimers, further details and supporting evidence.</div>
<h3><b>acenocoumarol</b></h3>
<p><font color="#444">Related Gene: CYP2C9<br>Detected Alleles: *1</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166202621 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> RNPGx: </b>Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.</div>
<div class="alert alert-info-red"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104979 target="_blank" style="color: #7C3A37"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>There are currently no recommendations for acenocoumarol dosing based on CYP2C9 genotypes.</div>
<p><font color="#444">Related Gene: VKORC1<br>Detected Alleles: rs9923231-CT; rs9934438-AG</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104938 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>Patients with the VKORC1 -1639 (rs9923231) AA genotype should be given 50% of the standard initial dose of acenocoumarol and undergo more frequent INR monitoring. There are no recommendation for patients with the VKORC1 -1639 AG genotype.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166202621 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> RNPGx: </b>Testing for VKORC1/CYP2C9 genotype is advisable to determine the optimal dose and to orient the prescription to an alternative therapeutic option such as a direct-action oral anticoagulant before initiating vitamin K antagonists (VKA) treatment. Testing is also advisable to explain an hemorrhagic event or VKA resistance after treatment initiation.</div>
<h3><b>azathioprine</b></h3>
<p><font color="#444">Related Gene: TPMT<br>Detected Alleles: *1</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166202521 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> RNPGx: </b>Testing for TPMT genotype and phenotype is recommended for patients who are receiving azathioprine as an immunosuppressant. A dose reduction should be considered for patients with intermediate TPMT activity, while a greater dose reduction or selection of an alternate drug should be considered for patients with low TPMT activity.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104933 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>Consider an alternate agent or extreme dose reduction of azathioprine for patients who are TPMT or NUDT15 poor metabolizers.  Start at 30-80% of target dose for patients who are TPMT or NUDT15 intermediate metabolizers.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104934 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>Select an alternative drug or reduce the initial dose of azathioprine for patients that are TPMT poor metabolizers and reduce initial dose for patients that are TPMT intermediate metabolizers.</div>
<h3><b>fluorouracil</b></h3>
<p><font color="#444">Related Gene: DPYD<br>Detected Alleles: rs67376798-TT; rs59086055-GG; rs1801265-AG; rs1801266-GG</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166202721 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> RNPGx: </b>The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) recommends testing for DPYD deficiency before initiating a treatment regimen based on 5-FU or capecitabine, with dose reductions for DPYD partial deficiency and contraindicates fluoropyrimidines in patients with complete deficiency.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104939 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>An alternative drug to fluorouracil is recommended for patients with a DPYD activity score of 0; if an alternative drug is not possible, the DPD activity should be determined and the initial dose adjusted accordingly. For patients with a DPYD activity score of 1 or 1.5, start with 50% of the standard dose or choose an alternative drug; adjustment of subsequent doses should be guided by toxicity and effectiveness. Patients with two partially functional alleles or one non-functional and one partially functional allele or two gene variants leading to partially functional alleles or a gene variant leading to a non-functional allele and a gene variant leading to a partially functional allele should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative for fluorouracil, as it is also metabolized by DPD. The DPWG evaluated DPYD genotyping as 'essential' and recommend DPYD testing prior to initiating fluoropyrimidines.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166254881 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> SEFF: </b>Testing for certain DPYD variants in patients who are candidates for fluoropyrimidine treatment is recommended. The guideline contraindicates fluoropyrimidines in DPYD poor metabolizers, while DYPD intermediate metabolizers should have a 50% reduction in starting dose.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166122686 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline for 5-fluorouracil and capecitabine recommends an alternative drug for patients who are DPYD poor metabolizers with an activity score of 0. In those who are poor metabolizers with an activity score of 0.5, an alternative drug is also recommended, but if this is not considered a suitable therapeutic option, 5-fluorouracil or capecitabine should be administered at a strongly reduced dose with early therapeutic drug monitoring. Patients who are intermediate metabolizers with an activity score of 1 or 1.5 should receive a dose reduction of 50%. Patients with the c.[2846A>T];[2846A>T] genotype may require a >50% dose reduction.</div>
<h3><b>enflurane</b></h3>
<p><font color="#444">Related Gene: CACNA1S<br>Detected Alleles: rs1800559-CC</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166180457 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.</div>
<p><font color="#444">Related Gene: RYR1<br>Detected Alleles: rs118192167-AA; rs118192178-CC; rs193922818-GG</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166180457 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.</div>
<h3><b>methoxyflurane</b></h3>
<p><font color="#444">Related Gene: CACNA1S<br>Detected Alleles: rs1800559-CC</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166180457 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.</div>
<p><font color="#444">Related Gene: RYR1<br>Detected Alleles: rs118192167-AA; rs118192178-CC; rs193922818-GG</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166180457 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.</div>
<h3><b>sevoflurane</b></h3>
<p><font color="#444">Related Gene: CACNA1S<br>Detected Alleles: rs1800559-CC</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166180457 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.</div>
<p><font color="#444">Related Gene: RYR1<br>Detected Alleles: rs118192167-AA; rs118192178-CC; rs193922818-GG</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166180457 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.</div>
<h3><b>halothane</b></h3>
<p><font color="#444">Related Gene: CACNA1S<br>Detected Alleles: rs1800559-CC</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166180457 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.</div>
<p><font color="#444">Related Gene: RYR1<br>Detected Alleles: rs118192167-AA; rs118192178-CC; rs193922818-GG</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166180457 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.</div>
<h3><b>isoflurane</b></h3>
<p><font color="#444">Related Gene: CACNA1S<br>Detected Alleles: rs1800559-CC</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166180457 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.</div>
<p><font color="#444">Related Gene: RYR1<br>Detected Alleles: rs118192167-AA; rs118192178-CC; rs193922818-GG</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166180457 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.</div>
<h3><b>succinylcholine</b></h3>
<p><font color="#444">Related Gene: CACNA1S<br>Detected Alleles: rs1800559-CC</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166180457 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.</div>
<p><font color="#444">Related Gene: RYR1<br>Detected Alleles: rs118192167-AA; rs118192178-CC; rs193922818-GG</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166180457 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.</div>
<h3><b>capecitabine</b></h3>
<p><font color="#444">Related Gene: DPYD<br>Detected Alleles: rs67376798-TT; rs1801265-AG</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166202721 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> RNPGx: </b>The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) recommends testing for DPYD deficiency before initiating a treatment regimen based on 5-FU or capecitabine, with dose reductions for DPYD partial deficiency and contraindicates fluoropyrimidines in patients with complete deficiency.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166254881 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> SEFF: </b>Testing for certain DPYD variants in patients who are candidates for fluoropyrimidine treatment is recommended. The guideline contraindicates fluoropyrimidines in DPYD poor metabolizers, while DYPD intermediate metabolizers should have a 50% reduction in starting dose.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104963 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>An alternative drug to capecitabine is recommended for patients with a DPYD activity score of 0; if an alternative drug is not possible, the DPD activity should be determined and the initial dose adjusted accordingly. For patients with a DPYD activity score of 1 or 1.5, start with 50% of the standard dose or choose an alternative drug; adjustment of subsequent doses should be guided by toxicity and effectiveness. Patients with two partially functional alleles or one non-functional and one partially functional allele or two gene variants leading to partially functional alleles or a gene variant leading to a non-functional allele and a gene variant leading to a partially functional allele should have their DPD activity determined or should avoid fluorouracil/capecitabine. Tegafur is not an alternative for capecitabine, as it is also metabolized by DPD. The DPWG evaluated DPYD genotyping as 'essential' and recommend DPYD testing prior to initiating fluoropyrimidines.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166109594 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline for 5-fluorouracil and capecitabine recommends an alternative drug for patients who are DPYD poor metabolizers with an activity score of 0. In those who are poor metabolizers with an activity score of 0.5, an alternative drug is also recommended, but if this is not considered a suitable therapeutic option, 5-fluorouracil or capecitabine should be administered at a strongly reduced dose with early therapeutic drug monitoring. Patients who are intermediate metabolizers with an activity score of 1 or 1.5 should receive a dose reduction of 50%. Patients with the c.[2846A>T];[2846A>T] genotype may require a >50% dose reduction.</div>
<h3><b>desflurane</b></h3>
<p><font color="#444">Related Gene: RYR1<br>Detected Alleles: rs118192167-AA; rs118192178-CC; rs193922818-GG</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166180457 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.</div>
<p><font color="#444">Related Gene: CACNA1S<br>Detected Alleles: rs1800559-CC</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166180457 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>The CPIC Dosing Guideline recommends that halogenated volatile anesthetics such as desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane and the depolarizing muscle relaxants succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). See full guideline for disclaimers, further details and supporting evidence.</div>
<h3><b>irinotecan</b></h3>
<p><font color="#444">Related Gene: UGT1A1<br>Detected Alleles: rs10929302-AG</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104951 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>Dose reductions are recommended for irinotecan for patients who are UGT1A1 *28/*28 or UGT1A1 PM, starting with 70% of starting dose and increasing as tolerated, guided by neutrophil count.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166127626 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> RNPGx: </b>A French joint working group comprising the National Pharmacogenetics Network (RNPGx) and the Group of Clinical Onco-pharmacology (GPCO-Unicancer) has published guidelines for the use of UGT1A1*28 genotype when prescribing irinotecan. They recommend that the dose of irinotecan be reduced in patients with the UGT1A1*28/*28 genotype, and that high-dose irinotecan (>=240 mg/m2) only be prescribed to patients with the UGT1A1*1/*1 genotype. The French National Network of Pharmacogenetics (RNPGx) included recommendations for irinotecan in  a 2017 paper on several anti-cancer drugs.</div>
<h3><b>tegafur</b></h3>
<p><font color="#444">Related Gene: DPYD<br>Detected Alleles: rs67376798-TT</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166122687 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>As of the November 2017 update of CPIC guidelines regarding fluoropyrimidine dosing, there are no longer dosing recommendations for tegafur based on DPYD  genotype. This is due to limited evidence regarding the impact of DPYD variants on tegafur toxicity risk. The guidelines currently only apply to 5-fluorouracil and capecitabine dosing.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166254881 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> SEFF: </b>Testing for certain DPYD variants in patients who are candidates for fluoropyrimidine treatment is recommended. The guideline contraindicates fluoropyrimidines in DPYD poor metabolizers, while DYPD intermediate metabolizers should have a 50% reduction in starting dose.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166104944 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> DPWG: </b>Choose an alternative drug to tegafur for patients with DPYD Activity Score of 0. For patients with a DPYD Activity Score of 1 or 1.5, avoid tegafur or start with a low dose and adjust the initial dose based on toxicity and efficacy. Fluorouracil and capecitabine are not alternatives for tegafur, as these are also metabolized by DPD. The DPWG evaluated DPYD genotyping as 'essential' and recommend DPYD testing prior to initiating fluoropyrimidines.</div>
<h3><b>ivacaftor</b></h3>
<p><font color="#444">Related Gene: CFTR<br>Detected Alleles: rs113993958-GG; rs77834169-CC; rs121908752-TT; rs80282562-GG; rs75541969-GG</font></p>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166114461 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CPIC: </b>Ivacaftor treatment is recommended only in cystic fibrosis (CF) patients that are either homozygous or heterozygous for certain CFTR variants.  See full guideline for disclaimers, further details and supporting evidence.</div>
<div class="alert alert-info-blue"><a href=https://pharmgkb.org/guidelineAnnotation/PA166178241 target="_blank"><i class="fa-solid fa-circle-info"></a></i><b> CFF: </b>Ivacaftor is suggested for some cystic fibrosis patients with specific CFTR gating mutations, including the G551D variants.Note that the guideline also suggests that ivacaftor should not be used in patients with at least one R117H mutation who are aged under 6 years or aged 12-17 years and with ppFEV1 greater than 90% predicted.</div>
<h2 id="diplotype detail"><b>Diplotype Detail</b></h2>
<p class="main_lead">PAnno predicts the diplotypes for PGx genes with star (*) or named allele information, which include ABCG2, CACNA1S, CFTR, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP4F2, DPYD, G6PD, MT-NR1, NUDT15, RYR1, SLCO1B1, TPMT, UGT1A1, and VKORC1. PAnno assumes that no variation occurs for the missing positions in the submitted VCFs, and the final inferred diplotypes are a composite ranking result.</p>
<h3><b>ABCG2: G/G</b></h3>
<table id="customer_table" border="1" cellspacing="0">
<tr><th>Position</th><th width="120px">rsID</th><th width="200px">Effect on Protein</th><th width="275px">Definition of Alleles</th><th width="200px">Detected Alleles</th></tr>
<tr><td>chr4:NC_000004.12:g.88131171G>T</td><td>rs2231142</td><td>p.Q141K</td><td>G:G</td><td>Missing</td></tr>
</table>
<h3><b>CACNA1S: Reference/Reference</b></h3>
<table id="customer_table" border="1" cellspacing="0">
<tr><th>Position</th><th width="120px">rsID</th><th width="200px">Effect on Protein</th><th width="275px">Definition of Alleles</th><th width="200px">Detected Alleles</th></tr>
<tr><td>chr1:NC_000001.11:g.201060815C>T</td><td>rs1800559</td><td>p.R1086H</td><td>Reference:C</td><td>C|C</td></tr>
<tr><td>chr1:NC_000001.11:g.201091993G>A</td><td>rs772226819</td><td>p.R174W</td><td>Reference:G</td><td>Missing</td></tr>
</table>
<h3><b>CFTR: ivacaftor non-responsive CFTR sequence/ivacaftor non-responsive CFTR sequence</b></h3>
<table id="customer_table" border="1" cellspacing="0">
<tr><th>Position</th><th width="120px">rsID</th><th width="200px">Effect on Protein</th><th width="275px">Definition of Alleles</th><th width="200px">Detected Alleles</th></tr>
<tr><td>chr7:NC_000007.14:g.117509035G>A</td><td>rs397508256</td><td>p.E56K</td><td>ivacaftor non-responsive CFTR sequence:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117509069C>T</td><td>rs368505753</td><td>p.P67L</td><td>ivacaftor non-responsive CFTR sequence:C</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117509089C>T</td><td>rs115545701</td><td>p.R74W</td><td>ivacaftor non-responsive CFTR sequence:C</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117530955C>A</td><td>rs397508537</td><td>p.D110E</td><td>ivacaftor non-responsive CFTR sequence:C</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117530953G>C</td><td>rs113993958</td><td>p.D110H</td><td>ivacaftor non-responsive CFTR sequence:G</td><td>G|G</td></tr>
<tr><td>chr7:NC_000007.14:g.117530974C>T</td><td>rs77834169</td><td>p.R117C</td><td>ivacaftor non-responsive CFTR sequence:C</td><td>C|C</td></tr>
<tr><td>chr7:NC_000007.14:g.117530975G>A</td><td>rs78655421</td><td>p.R117H</td><td>ivacaftor non-responsive CFTR sequence:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117534318G>A</td><td>rs80282562</td><td>p.G178R</td><td>ivacaftor non-responsive CFTR sequence:G</td><td>G|G</td></tr>
<tr><td>chr7:NC_000007.14:g.117534363G>A</td><td>rs397508759</td><td>p.E193K</td><td>ivacaftor non-responsive CFTR sequence:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117534368A>G</td><td>rs397508761</td><td>Intronic</td><td>ivacaftor non-responsive CFTR sequence:A</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117535285T>G</td><td>rs121908752</td><td>p.L206W</td><td>ivacaftor non-responsive CFTR sequence:T</td><td>T|T</td></tr>
<tr><td>chr7:NC_000007.14:g.117540270G>A</td><td>rs77932196</td><td>p.R347H</td><td>ivacaftor non-responsive CFTR sequence:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117540285G>A</td><td>rs121908753</td><td>p.R352Q</td><td>ivacaftor non-responsive CFTR sequence:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117548795C>A</td><td>rs74551128</td><td>p.A455E</td><td>ivacaftor non-responsive CFTR sequence:C</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117587800G>A</td><td>rs121908755</td><td>p.S549N</td><td>ivacaftor non-responsive CFTR sequence:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117587799A>C</td><td>rs121908757</td><td>p.S549R</td><td>ivacaftor non-responsive CFTR sequence:A</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117587801T>G</td><td>rs121909005</td><td>p.S549R</td><td>ivacaftor non-responsive CFTR sequence:T</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117587805G>A</td><td>rs121909013</td><td>p.G551S</td><td>ivacaftor non-responsive CFTR sequence:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117587806G>A</td><td>rs75527207</td><td>p.G551D</td><td>ivacaftor non-responsive CFTR sequence:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117590409A>G</td><td>rs397508288</td><td>p.D579G</td><td>ivacaftor non-responsive CFTR sequence:A</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117594930G>T</td><td>rs397508387</td><td>p.E831X</td><td>ivacaftor non-responsive CFTR sequence:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117602868G>A</td><td>rs80224560</td><td>Intronic</td><td>ivacaftor non-responsive CFTR sequence:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117603708C>T</td><td>rs397508442</td><td>p.S945L</td><td>ivacaftor non-responsive CFTR sequence:C</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117606695C>T</td><td>rs141033578</td><td>p.S977F</td><td>ivacaftor non-responsive CFTR sequence:C</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117611555A>G</td><td>rs76151804</td><td>Intronic</td><td>ivacaftor non-responsive CFTR sequence:A</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117611595T>G</td><td>rs150212784</td><td>p.F1052V</td><td>ivacaftor non-responsive CFTR sequence:T</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117611620A>C</td><td>rs397508513</td><td>p.K1060T</td><td>ivacaftor non-responsive CFTR sequence:A</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117611640G>A</td><td>rs121909020</td><td>p.A1067T</td><td>ivacaftor non-responsive CFTR sequence:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117611646G>A</td><td>rs200321110</td><td>p.G1069R</td><td>ivacaftor non-responsive CFTR sequence:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117611650G>A</td><td>rs78769542</td><td>p.R1070Q</td><td>ivacaftor non-responsive CFTR sequence:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117611649C>T</td><td>rs202179988</td><td>p.R1070W</td><td>ivacaftor non-responsive CFTR sequence:C</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117611663T>A</td><td>rs186045772</td><td>p.F1074L</td><td>ivacaftor non-responsive CFTR sequence:T</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117614699G>C</td><td>rs75541969</td><td>p.D1152H</td><td>ivacaftor non-responsive CFTR sequence:G</td><td>G|G</td></tr>
<tr><td>chr7:NC_000007.14:g.117639961C>T</td><td>rs75039782</td><td>Intronic</td><td>ivacaftor non-responsive CFTR sequence:C</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117642451G>A</td><td>rs267606723</td><td>p.G1244E</td><td>ivacaftor non-responsive CFTR sequence:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117642472G>A</td><td>rs74503330</td><td>p.S1251N</td><td>ivacaftor non-responsive CFTR sequence:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117642483T>C</td><td>rs121909041</td><td>p.S1255P</td><td>ivacaftor non-responsive CFTR sequence:T</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117642528G>A</td><td>rs11971167</td><td>p.D1270N</td><td>ivacaftor non-responsive CFTR sequence:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.117664770G>A</td><td>rs193922525</td><td>p.G1349D</td><td>ivacaftor non-responsive CFTR sequence:G</td><td>Missing</td></tr>
</table>
<h3><b>CYP2B6: *5/*6</b></h3>
<table id="customer_table" border="1" cellspacing="0">
<tr><th>Position</th><th width="120px">rsID</th><th width="200px">Effect on Protein</th><th width="275px">Definition of Alleles</th><th width="200px">Detected Alleles</th></tr>
<tr><td>chr19:NC_000019.10:g.40991224T>C</td><td>rs34223104</td><td></td><td>*6:T; *5:T</td><td>T|T</td></tr>
<tr><td>chr19:NC_000019.10:g.40991367A>T</td><td>rs34883432</td><td>p.Q21L</td><td>*6:A; *5:A</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.40991369C>T</td><td>rs8192709</td><td>p.R22C</td><td>*6:C; *5:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.40991381A>T</td><td>rs33973337</td><td>p.T26S</td><td>*6:A; *5:A</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.40991388A>G</td><td>rs33980385</td><td>p.D28G</td><td>*6:A; *5:A</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.40991390C>A</td><td>rs33926104</td><td>p.R29S</td><td>*6:C; *5:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.40991391G>C</td><td>rs34284776</td><td>p.R29P</td><td>*6:G; *5:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.40991441A>G</td><td>rs35303484</td><td>p.M46V</td><td>*6:A; *5:A</td><td>A|A</td></tr>
<tr><td>chr19:NC_000019.10:g.41004015T>A</td><td>rs281864907</td><td>p.Y62X</td><td>*6:T; *5:T</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.41004125G>A</td><td>rs36060847</td><td>p.G99E</td><td>*6:G; *5:G</td><td>G|G</td></tr>
<tr><td>chr19:NC_000019.10:g.41004158G>T</td><td>rs186335453</td><td>p.G110V</td><td>*6:G; *5:G</td><td>G|G</td></tr>
<tr><td>chr19:NC_000019.10:g.41004303T>C</td><td>rs139801276</td><td>p.I114T</td><td>*6:T; *5:T</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.41004377A>G</td><td>rs12721655</td><td>p.K139E</td><td>*6:A; *5:A</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.41004381G>A</td><td>rs35773040</td><td>p.R140Q</td><td>*6:G; *5:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.41004406G>T</td><td>rs145884402</td><td>p.E148D</td><td>*6:G; *5:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.41006919C>G</td><td>rs3826711</td><td>p.P167A</td><td>*6:C; *5:C</td><td>C|C</td></tr>
<tr><td>chr19:NC_000019.10:g.41006923C>T</td><td>rs36056539</td><td>p.T168I</td><td>*6:C; *5:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.41006936G>T</td><td>rs3745274</td><td>p.Q172H</td><td>*6:T; *5:G</td><td>G|T</td></tr>
<tr><td>chr19:NC_000019.10:g.41006968T>G</td><td>rs373489637</td><td>p.V183G</td><td>*6:T; *5:T</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.41007013T>C</td><td>rs36079186</td><td>p.M198T</td><td>*6:T; *5:T</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.41009350C>A</td><td>rs45482602</td><td>p.S259R</td><td>*6:C; *5:C</td><td>C|C</td></tr>
<tr><td>chr19:NC_000019.10:g.41009358A>G</td><td>rs2279343</td><td>p.K262R</td><td>*6:G; *5:A</td><td>A|G</td></tr>
<tr><td>chr19:NC_000019.10:g.41010006G>C</td><td>rs139029625</td><td>p.A279P</td><td>*6:G; *5:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.41010088C>G</td><td>rs34698757</td><td>p.T306S</td><td>*6:C; *5:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.41010108C>A</td><td>rs193922917</td><td>p.L313I</td><td>*6:C; *5:C</td><td>C|C</td></tr>
<tr><td>chr19:NC_000019.10:g.41012316T>C</td><td>rs28399499</td><td>p.I328T</td><td>*6:T; *5:T</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.41012339C>T</td><td>rs34826503</td><td>p.R336C</td><td>*6:C; *5:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.41012465C>T</td><td>rs34097093</td><td>p.R378X</td><td>*6:C; *5:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.41012693T>A</td><td>rs35979566</td><td>p.I391N</td><td>*6:T; *5:T</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.41012740G>A</td><td>rs193922918</td><td>p.A407T</td><td>*6:G; *5:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.41012803C>A</td><td>rs35010098</td><td>p.P428T</td><td>*6:C; *5:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.41016726A>G</td><td>rs3211369</td><td>p.M459V</td><td>*6:A; *5:A</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.41016778G>A</td><td>rs564083989</td><td>p.G476D</td><td>*6:G; *5:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.41016805A>T</td><td></td><td>p.Q485L</td><td>*6:A; *5:A</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.41016810C>A; g.41016810C>T</td><td>rs3211371</td><td>p.R487S; p.R487C</td><td>*6:C; *5:T</td><td>C|T</td></tr>
</table>
<h3><b>CYP2C8: *1/*4</b></h3>
<table id="customer_table" border="1" cellspacing="0">
<tr><th>Position</th><th width="120px">rsID</th><th width="200px">Effect on Protein</th><th width="275px">Definition of Alleles</th><th width="200px">Detected Alleles</th></tr>
<tr><td>chr10:NC_000010.11:g.95067273C>T</td><td>rs11572080</td><td>p.R139K</td><td>*4:C; *1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.95067218del</td><td>rs72558196</td><td>p.T159fs</td><td>*4:T; *1:T</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.95064931C>T</td><td>rs142886225</td><td>p.G171S</td><td>*4:C; *1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.95064901C>T</td><td>rs41286886</td><td>p.V181I</td><td>*4:C; *1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.95064886G>C; g.95064886G>A</td><td>rs72558195</td><td>p.R186G; p.R186X</td><td>*4:G; *1:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.95058485A>C</td><td></td><td>p.I223M</td><td>*4:A; *1:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.95058442C>G</td><td>rs188934928</td><td>p.A238P</td><td>*4:C; *1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.95058424T>C</td><td>rs11572102</td><td>p.I244V</td><td>*4:T; *1:T</td><td>T|T</td></tr>
<tr><td>chr10:NC_000010.11:g.95058414T>C</td><td>rs769460274</td><td>p.K247R</td><td>*4:T; *1:T</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.95058362G>C</td><td>rs1058930</td><td>p.I264M</td><td>*4:C; *1:G</td><td>G|C</td></tr>
<tr><td>chr10:NC_000010.11:g.95058349T>A</td><td>rs11572103</td><td>p.I269F</td><td>*4:T; *1:T</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.95045951C>A</td><td>rs78637571</td><td>p.E274X</td><td>*4:C; *1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.95043047A>G</td><td>rs146806199</td><td>p.I331T</td><td>*4:A; *1:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.95042958G>A</td><td>rs45438799</td><td>p.L361F</td><td>*4:G; *1:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.95042890C>A</td><td></td><td>p.K383N</td><td>*4:C; *1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.95038992T>C</td><td>rs10509681</td><td>p.K399R</td><td>*4:T; *1:T</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.95037219_95037221del</td><td>rs3832694</td><td>p.461delV</td><td>*4:ACA; *1:ACA</td><td>Missing</td></tr>
</table>
<h3><b>CYP2C9: *1/*1</b></h3>
<table id="customer_table" border="1" cellspacing="0">
<tr><th>Position</th><th width="120px">rsID</th><th width="200px">Effect on Protein</th><th width="275px">Definition of Alleles</th><th width="200px">Detected Alleles</th></tr>
<tr><td>chr10:NC_000010.11:g.94942306C>T</td><td>rs1289704600</td><td>p.A149V</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94942308C>T</td><td>rs17847037</td><td>p.R150C</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94947439G>T</td><td></td><td>p.Q214H</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94986136A>C</td><td>rs1254213342</td><td>p.N418T</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94942213_94942222del</td><td>rs1304490498</td><td>p.K118fs</td><td>*1:AGAAATGGAA</td><td>AGAAATGGAA|AGAAATGGAA</td></tr>
<tr><td>chr10:NC_000010.11:g.94949283del</td><td>rs9332131</td><td>p.K273fs</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94986042A>G</td><td>rs764211126</td><td>p.I387V</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94986073A>C</td><td>rs72558193</td><td>p.D397A</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94988852C>T</td><td>rs776908257</td><td>p.R433W</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94941976G>C</td><td></td><td>p.G96A</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94942309G>A; g.94942309G>T</td><td>rs7900194</td><td>p.R150H; p.R150L</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94947869A>G</td><td></td><td>p.D191G</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94981302C>A</td><td>rs1250577724</td><td>p.L361I</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94938683A>G</td><td>rs114071557</td><td>p.M1V</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94938737C>A</td><td>rs67807361</td><td>p.L19I</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94938771C>T</td><td>rs142240658</td><td>p.P30L</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94938803A>G</td><td>rs2031308986</td><td>p.N41D</td><td>*1:A</td><td>A|A</td></tr>
<tr><td>chr10:NC_000010.11:g.94938828A>G</td><td>rs564813580</td><td>p.D49G</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94941897G>C</td><td>rs371055887</td><td>p.G70R</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94941915G>A</td><td></td><td>p.V76M</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94941958T>C</td><td>rs72558187</td><td>p.L90P</td><td>*1:T</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94941982G>T</td><td>rs762239445</td><td>p.G98V</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94942018T>C</td><td></td><td>p.F110S</td><td>*1:T</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94942216A>G</td><td>rs774607211</td><td>p.K119R</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94942230C>T</td><td>rs767576260</td><td>p.R124W</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94942231G>A</td><td>rs12414460</td><td>p.R124Q</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94942233C>T</td><td>rs375805362</td><td>p.R125C</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94942234G>A; g.94942234G>T</td><td>rs72558189</td><td>p.R125H; p.R125L</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94942249C>G; g.94942249C>T</td><td>rs200965026</td><td>p.T130R; p.T130M</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94942254C>T</td><td>rs199523631</td><td>p.R132W</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94942255G>A</td><td>rs200183364</td><td>p.R132Q</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94942290C>T</td><td>rs1799853</td><td>p.R144C</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94942291G>A</td><td>rs141489852</td><td>p.R144H</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94942305G>A</td><td>rs754487195</td><td>p.A149T</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94947782C>A</td><td>rs72558190</td><td>p.S162X</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94947785C>T</td><td>rs774550549</td><td>p.P163L</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94988855A>T</td><td></td><td>p.I434F</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94981296A>C</td><td>rs1057910</td><td>p.I359L</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94988917G>C</td><td>rs769942899</td><td>p.Q454H</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94981225G>A</td><td>rs367826293</td><td>p.R335Q</td><td>*1:G</td><td>G|G</td></tr>
<tr><td>chr10:NC_000010.11:g.94981250C>A</td><td>rs750820937</td><td>p.S343R</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94988955T>C</td><td>rs767284820</td><td>p.L467P</td><td>*1:T</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94981301C>G</td><td>rs28371686</td><td>p.D360E</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94989020C>T</td><td>rs9332239</td><td>p.P489S</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94981305C>G</td><td>rs578144976</td><td>p.L362V</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94988925A>G</td><td>rs202201137</td><td>p.N457S</td><td>*1:A</td><td>A|A</td></tr>
<tr><td>chr10:NC_000010.11:g.94988984G>A</td><td>rs781583846</td><td>p.A477T</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94989023G>T</td><td>rs868182778</td><td>p.V490F</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94981365C>T</td><td></td><td>p.P382S</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94988880G>T</td><td></td><td>p.G442V</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94947907A>C</td><td></td><td>p.N204H</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94947917T>C</td><td>rs1326630788</td><td>p.I207T</td><td>*1:T</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94947938A>T</td><td>rs2031531005</td><td>p.Q214L</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94949129A>G</td><td></td><td>p.I222V</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94949144C>T</td><td></td><td>p.P227S</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94949217A>G</td><td>rs2256871</td><td>p.H251R</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94949280A>G</td><td>rs9332130</td><td>p.E272G</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94972119C>A</td><td>rs182132442</td><td>p.P279T</td><td>*1:C</td><td>C|C</td></tr>
<tr><td>chr10:NC_000010.11:g.94972123C>G</td><td></td><td>p.S280C</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94972134A>G</td><td></td><td>p.I284V</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94972179A>G</td><td>rs72558192</td><td>p.T299A</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94972180C>G</td><td>rs988617574</td><td>p.T299R</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94972233C>T</td><td>rs1237225311</td><td>p.P317S</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94981199G>T</td><td></td><td>p.E326D</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94981201T>C</td><td>rs57505750</td><td>p.I327T</td><td>*1:T</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94981224C>T</td><td>rs28371685</td><td>p.R335W</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94981230C>A</td><td>rs1274535931</td><td>p.P337T</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94981281G>A</td><td>rs749060448</td><td>p.E354K</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94981297T>C</td><td>rs56165452</td><td>p.I359T</td><td>*1:T</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94981371G>A</td><td>rs542577750</td><td>splicing defect</td><td>*1:G</td><td>Missing</td></tr>
</table>
<h3><b>CYP2C19: *2/*2</b></h3>
<table id="customer_table" border="1" cellspacing="0">
<tr><th>Position</th><th width="120px">rsID</th><th width="200px">Effect on Protein</th><th width="275px">Definition of Alleles</th><th width="200px">Detected Alleles</th></tr>
<tr><td>chr10:NC_000010.11:g.94761900C>T</td><td>rs12248560</td><td>p.expression</td><td>*2:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94762706A>G</td><td>rs28399504</td><td>p.M1V</td><td>*2:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94762712C>T</td><td>rs367543002</td><td>p.P3S</td><td>*2:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94762715T>C</td><td>rs367543003</td><td>p.F4L</td><td>*2:T</td><td>T|T</td></tr>
<tr><td>chr10:NC_000010.11:g.94762755T>C</td><td>rs55752064</td><td>p.L17P</td><td>*2:T</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94762760A>C</td><td>rs17882687</td><td>p.I19L</td><td>*2:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94762788A>T</td><td>rs1564656981</td><td>p.K28I</td><td>*2:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94762856A>G</td><td>rs1564657013</td><td>p.S51G</td><td>*2:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94775106C>T</td><td>rs145328984</td><td>p.R73C</td><td>*2:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94775121C>T</td><td>rs1564660997</td><td>p.H78Y</td><td>*2:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94775160G>C</td><td>rs118203756</td><td>p.G91R</td><td>*2:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94775185A>G</td><td>rs1288601658</td><td>p.H99R</td><td>*2:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94775367A>G</td><td>rs12769205</td><td>splicing defect</td><td>*2:G</td><td>G|G</td></tr>
<tr><td>chr10:NC_000010.11:g.94775416T>C</td><td>rs41291556</td><td>p.W120R</td><td>*2:T</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94775423A>C</td><td>rs17885179</td><td>p.E122A</td><td>*2:A</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94775453G>A</td><td>rs72552267</td><td>p.R132Q</td><td>*2:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94775489G>A</td><td>rs17884712</td><td>p.R144H</td><td>*2:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94775507G>A</td><td>rs58973490</td><td>p.R150H</td><td>*2:R</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94780574G>C</td><td>rs140278421</td><td>p.R186P</td><td>*2:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94780579G>A</td><td>rs370803989</td><td>p.D188N</td><td>*2:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94780653G>A</td><td>rs4986893</td><td>p.W212X</td><td>*2:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94781858C>T</td><td>rs6413438</td><td>p.P227L</td><td>*2:C</td><td>C|C</td></tr>
<tr><td>chr10:NC_000010.11:g.94781859G>A</td><td>rs4244285</td><td>splicing defect</td><td>*2:A</td><td>A|A</td></tr>
<tr><td>chr10:NC_000010.11:g.94781944G>A</td><td>rs375781227</td><td>p.D256N</td><td>*2:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94781999T>A</td><td>rs72558186</td><td>splicing defect</td><td>*2:T</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94842861G>A</td><td>rs138142612</td><td>p.R329H</td><td>*2:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94842866A>G</td><td>rs3758581</td><td>p.I331V</td><td>*2:G</td><td>G|G</td></tr>
<tr><td>chr10:NC_000010.11:g.94842879G>A</td><td>rs118203757</td><td>p.R335Q</td><td>*2:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94842995G>A</td><td>rs113934938</td><td>p.V374I</td><td>*2:G</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94849995C>T</td><td>rs17879685</td><td>p.R410C</td><td>*2:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94852738C>T</td><td>rs56337013</td><td>p.R433W</td><td>*2:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94852765C>T</td><td>rs192154563</td><td>p.R442C</td><td>*2:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94852785C>G</td><td>rs118203759</td><td>p.F448L</td><td>*2:C</td><td>Missing</td></tr>
<tr><td>chr10:NC_000010.11:g.94852914A>C</td><td>rs55640102</td><td>p.X491C</td><td>*2:A</td><td>Missing</td></tr>
</table>
<h3><b>CYP2D6: *4/*35</b></h3>
<table id="customer_table" border="1" cellspacing="0">
<tr><th>Position</th><th width="120px">rsID</th><th width="200px">Effect on Protein</th><th width="275px">Definition of Alleles</th><th width="200px">Detected Alleles</th></tr>
<tr><td>chr22:NC_000022.11:g.42129042T>C</td><td>rs1135824</td><td>p.N166D</td><td>*4:T; *35:T</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129033C>T; g.42129033C>A</td><td>rs5030865</td><td>p.G169R; p.G169X</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128945C>T</td><td>rs3892097</td><td>splicing defect</td><td>*4:T; *35:C</td><td>C|T</td></tr>
<tr><td>chr22:NC_000022.11:g.42128934AAAGGGGCG[3]; g.42128934_42128942dup</td><td>rs72549356</td><td>p.174_175insFRPx2; p.174_175insFRP</td><td>*4:AAAGGGGCG; *35:AAAGGGGCG</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128878C>A</td><td></td><td>p.C191F</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128813G>A</td><td>rs150163869</td><td></td><td>*4:R; *35:R</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128351C>T</td><td>rs377725912</td><td>splicing defect</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42130729del</td><td></td><td>p.L22X</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42130655dup</td><td>rs774671100</td><td>p.L47fs</td><td>*4:A; *35:A</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129799G>C</td><td>rs76802407</td><td>p.D97E</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129084del</td><td>rs5030655</td><td>p.W152fs</td><td>*4:A; *35:A</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128817dup</td><td>rs72549354</td><td>p.L213fs</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128796del</td><td></td><td>p.L220fs</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128251_42128254del</td><td>rs72549353</td><td>p.T256fs</td><td>*4:TTAG; *35:TTAG</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128242del</td><td>rs35742686</td><td>p.R259fs</td><td>*4:T; *35:T</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128218dup</td><td>rs72549352</td><td>p.R269fs</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128199TCAG[1]</td><td>rs72549351</td><td>p.T272fs</td><td>*4:TCAG(2); *35:TCAG(2)</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128176_42128178del</td><td>rs5030656</td><td>p.K281del</td><td>*4:TCT; *35:TCT</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127963del</td><td>rs267608279</td><td>p.S288fs</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127846_42127864del</td><td>rs730882170</td><td>p.M321fs</td><td>*4:CACATCCGGATGTAGGATC; *35:CACATCCGGATGTAGGATC</td><td>CACATCCGGATGTAGGATC|CACATCCGGATGTAGGATC</td></tr>
<tr><td>chr22:NC_000022.11:g.42126982_42126983del</td><td>rs757396767</td><td>p.L395fs</td><td>*4:AG; *35:AG</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126658_42126666dup</td><td>rs765776661</td><td>p.468_470dupVPT</td><td>*4:AGTGGGCAC; *35:AGTGGGCAC</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127973T>C</td><td>rs1135829</td><td>p.N285S</td><td>*4:T; *35:T</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129809T>C</td><td>rs28371704</td><td>p.H94R</td><td>*4:Y; *35:T</td><td>T|C</td></tr>
<tr><td>chr22:NC_000022.11:g.42129770G>T; g.42129770G>A</td><td>rs28371706</td><td>p.Y107I; p.T107N</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129071T>G; g.42129071T>A</td><td>rs267608302</td><td>p.E156A; p.E156V</td><td>*4:T; *35:T</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128903_42128904insTA</td><td></td><td>p.S183X</td><td>*4:del; *35:del</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127922A>G</td><td>rs1406719554</td><td>p.L302P</td><td>*4:A; *35:A</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129183C>T</td><td>rs374616348</td><td>p.V119M</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42130778G>A</td><td>rs773790593</td><td>p.A5V</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42130773C>T</td><td>rs72549358</td><td>p.V7M</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42130719G>A</td><td>rs267608313</td><td>p.R25W</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42130715C>T</td><td>rs28371696</td><td>p.R26H</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42130710G>A</td><td>rs138100349</td><td>p.R28C</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42130692G>A</td><td>rs1065852</td><td>p.P34S</td><td>*4:R; *35:G</td><td>G|A</td></tr>
<tr><td>chr22:NC_000022.11:g.42130668C>T</td><td>rs5030862</td><td>p.G42R</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42130667C>T</td><td>rs118203758</td><td>p.G42E</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129910C>G</td><td>rs201377835</td><td>splicing defect</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129906G>A</td><td>rs267608311</td><td>p.R62W</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129887A>C</td><td>rs1456026511</td><td>p.V68G</td><td>*4:A; *35:A</td><td>A|A</td></tr>
<tr><td>chr22:NC_000022.11:g.42129836G>A</td><td>rs267608310</td><td>p.A85V</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129827C>G</td><td>rs267608276</td><td>p.R88P</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129821G>A</td><td>rs267608309</td><td>p.A90V</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129819G>T</td><td>rs28371703</td><td>p.L91M</td><td>*4:K; *35:G</td><td>G|T</td></tr>
<tr><td>chr22:NC_000022.11:g.42129780C>T</td><td>rs267608308</td><td>p.V104M</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129779A>G</td><td>rs76187628</td><td>p.V104A</td><td>*4:A; *35:A</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129771T>A</td><td>rs74802369</td><td>p.T107S</td><td>*4:T; *35:T</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129765T>C</td><td>rs78459009</td><td>p.I109V</td><td>*4:T; *35:T</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129759C>T</td><td>rs535642512</td><td>p.G111S</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129180A>T</td><td>rs1135822</td><td>p.F120I</td><td>*4:A; *35:A</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129174C>A</td><td>rs1135823</td><td>p.A122S</td><td>*4:C; *35:C</td><td>C|C</td></tr>
<tr><td>chr22:NC_000022.11:g.42129166A>C</td><td>rs766391487</td><td>p.Y124X</td><td>*4:A; *35:A</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129155C>T</td><td>rs1180015037</td><td>p.W128X</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129134G>A</td><td>rs781457579</td><td>p.S135F</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129132C>T</td><td>rs61736512</td><td>p.V136M</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129130C>G</td><td>rs1058164</td><td></td><td>*4:S; *35:G</td><td>G|G</td></tr>
<tr><td>chr22:NC_000022.11:g.42129113A>G</td><td>rs375135093</td><td>p.L142S</td><td>*4:A; *35:A</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129098T>C</td><td>rs569229126</td><td>p.K147R</td><td>*4:T; *35:T</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129087G>C</td><td>rs78482768</td><td>p.Q151E</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129075C>T</td><td>rs28371710</td><td>p.E155K</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129056C>G</td><td></td><td>p.C161S</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129037G>T</td><td>rs1135825</td><td>p.H167Q</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42129036A>C</td><td>rs1135826</td><td>p.S168A</td><td>*4:A; *35:A</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126914C>T</td><td>rs28371733</td><td>p.E418K</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127457C>T</td><td>rs77312092</td><td>p.R388H</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126956T>G</td><td>rs1931013246</td><td>p.K404Q</td><td>*4:T; *35:T</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127523A>G</td><td>rs1555888910</td><td>p.F366S</td><td>*4:A; *35:A</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126896G>A</td><td>rs763964554</td><td>p.Q424X</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127514A>G</td><td></td><td>p.I369T</td><td>*4:A; *35:A</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126877G>A</td><td>rs3021084</td><td>p.P430L</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126752C>T</td><td>rs569439709</td><td>p.G439D</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126749C>T</td><td>rs267608319</td><td>p.R440H</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126747G>A</td><td>rs730882251</td><td>p.R441C</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126746C>T</td><td>rs532668079</td><td>p.R441H</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127512C>T</td><td>rs61745683</td><td>p.V370I</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127473C>T</td><td>rs75386357</td><td>p.E383K</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126735C>T</td><td>rs751092905</td><td>p.G445R</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126719C>T</td><td>rs369177208</td><td>p.R450H</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126697G>T</td><td></td><td>p.F457L</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126681G>C</td><td></td><td>p.H463D</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126663G>C</td><td>rs1135833</td><td>p.P469A</td><td>*4:S; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126660T>C</td><td>rs1135835</td><td>p.T470A</td><td>*4:Y; *35:T</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126647C>T</td><td>rs141756339</td><td>p.R474Q</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126636G>A</td><td>rs28371735</td><td>p.H478Y</td><td>*4:R; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126635T>G</td><td>rs766507177</td><td>p.H478P</td><td>*4:K; *35:T</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126634A>C</td><td></td><td>p.H478Q</td><td>*4:A; *35:A</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126633C>G</td><td></td><td>p.G479R</td><td>*4:S; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126627A>C</td><td></td><td>p.F481V</td><td>*4:M; *35:A</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126624C>T</td><td>rs74478221</td><td>p.A482T</td><td>*4:Y; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126623G>C</td><td>rs75467367</td><td>p.A482G</td><td>*4:S; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126611C>G</td><td>rs1135840</td><td>p.S486T</td><td>*4:S; *35:G</td><td>G|G</td></tr>
<tr><td>chr22:NC_000022.11:g.42126605G>A</td><td>rs568495591</td><td>p.S488F</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126578C>T</td><td>rs1440526469</td><td>p.R497H</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128879A>G</td><td></td><td>p.C191R</td><td>*4:A; *35:A</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128848C>T</td><td>rs745365204</td><td>p.R201H</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128812A>G</td><td>rs199535154</td><td>p.L213P</td><td>*4:A; *35:A</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128329G>A</td><td>rs373813287</td><td>p.L230F</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128325A>G</td><td>rs17002853</td><td>p.L231P</td><td>*4:A; *35:A</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128308C>A</td><td>rs28371717</td><td>p.A237S</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128272T>G</td><td></td><td>p.T249P</td><td>*4:T; *35:T</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128235G>A</td><td>rs267608297</td><td>p.T261I</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128217G>T</td><td>rs148769737</td><td>p.P267H</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128212G>A</td><td>rs367543000</td><td>p.R269X</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128185C>T</td><td>rs77913725</td><td>p.E278K</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42128181A>T</td><td>rs1135828</td><td>p.M279K</td><td>*4:A; *35:A</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127941G>A</td><td>rs16947</td><td>p.R296C</td><td>*4:R; *35:A</td><td>G|A</td></tr>
<tr><td>chr22:NC_000022.11:g.42127938T>G</td><td>rs949717872</td><td>p.I297L</td><td>*4:T; *35:T</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127899T>C</td><td></td><td>p.T310A</td><td>*4:T; *35:T</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127856T>G</td><td>rs5030867</td><td>p.H324P</td><td>*4:T; *35:T</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127852C>T</td><td>rs79292917</td><td>splicing defect</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127841C>G</td><td>rs72549349</td><td>splicing defect</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127803C>T</td><td>rs28371725</td><td>splicing defect</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127631C>G</td><td>rs141009491</td><td>p.R330P</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127619T>G</td><td>rs72549348</td><td>p.E334A</td><td>*4:T; *35:T</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127611C>T</td><td>rs78209835</td><td>p.D337N</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127610T>C</td><td>rs748712690</td><td>p.D337G</td><td>*4:T; *35:T</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127608C>T</td><td>rs59421388</td><td>p.V338M</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127602C>T</td><td></td><td>p.G340R</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127593G>C</td><td>rs267608295</td><td>p.R343G</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127590G>A</td><td>rs72549347</td><td>p.R344X</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127589C>T</td><td>rs76088846</td><td>p.R344Q</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127565T>C</td><td>rs61736517</td><td>p.H352R</td><td>*4:T; *35:T</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127556T>C</td><td>rs202102799</td><td>p.Y355C</td><td>*4:T; *35:T</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42127530_42127531insAC</td><td>rs72549346</td><td>p.Q364fs</td><td>*4:del; *35:del</td><td>del|del</td></tr>
<tr><td>chr22:NC_000022.11:g.42127526C>T</td><td>rs1058172</td><td>p.R365H</td><td>*4:Y; *35:C</td><td>C|T</td></tr>
<tr><td>chr22:NC_000022.11:g.42126938C>T</td><td>rs769157652</td><td>p.E410K</td><td>*4:C; *35:C</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42126926G>A</td><td>rs747089665</td><td>p.R414C</td><td>*4:G; *35:G</td><td>Missing</td></tr>
<tr><td>chr22:NC_000022.11:g.42130761C>T</td><td>rs769258</td><td>p.V11M</td><td>*4:C; *35:T</td><td>C|T</td></tr>
</table>
<h3><b>CYP3A4: *1/*1</b></h3>
<table id="customer_table" border="1" cellspacing="0">
<tr><th>Position</th><th width="120px">rsID</th><th width="200px">Effect on Protein</th><th width="275px">Definition of Alleles</th><th width="200px">Detected Alleles</th></tr>
<tr><td>chr7:NC_000007.14:g.99784075G>C</td><td>rs188389063</td><td>p.L3V</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99784038A>G</td><td>rs12721634</td><td>p.L15P</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99784018G>C</td><td>rs570051168</td><td>p.L22V</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99778079C>T</td><td>rs56324128</td><td>p.G56D</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99770217A>T</td><td>rs1449865051</td><td>p.F113I</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99770202T>C</td><td>rs55951658</td><td>p.I118V</td><td>*1:T</td><td>T|T</td></tr>
<tr><td>chr7:NC_000007.14:g.99770166G>A</td><td>rs778013004</td><td>p.R130X</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99770165C>T</td><td>rs72552799</td><td>p.R130Q</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99769805G>A</td><td>rs57409622</td><td>p.R162W</td><td>*1:G</td><td>G|G</td></tr>
<tr><td>chr7:NC_000007.14:g.99769804C>T</td><td>rs4986907</td><td>p.R162Q</td><td>*1:C</td><td>C|C</td></tr>
<tr><td>chr7:NC_000007.14:g.99769781C>T</td><td>rs72552798</td><td>p.V170I</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99769769C>G</td><td>rs4986908</td><td>p.D174H</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99768693G>A</td><td>rs35599367</td><td>splicing defect</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99768470G>C</td><td>rs12721627</td><td>p.T185S</td><td>*1:G</td><td>G|G</td></tr>
<tr><td>chr7:NC_000007.14:g.99768458A>G</td><td>rs4987161</td><td>p.F189S</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99768424T>A</td><td>rs113667357</td><td>p.Q200H</td><td>*1:T</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99768371G>C</td><td>rs55901263</td><td>p.P218R</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99768360A>G</td><td>rs55785340</td><td>p.S222P</td><td>*1:A</td><td>A|A</td></tr>
<tr><td>chr7:NC_000007.14:g.99766440G>A</td><td>rs138105638</td><td>p.R268X</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99766412dup</td><td>rs4646438</td><td>p.D277fs</td><td>*1:T</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99764003A>G</td><td>rs28371759</td><td>p.L293P</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99763925T>C</td><td>rs201821708</td><td>p.Y319C</td><td>*1:T</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99763909G>T</td><td>rs1303250043</td><td>p.H324Q</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99763877A>G</td><td>rs368296206</td><td>p.I335T</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99763843C>T</td><td>rs2242480</td><td>p.expression</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99762206G>A</td><td>rs67784355</td><td>p.T363M</td><td>*1:G</td><td>G|G</td></tr>
<tr><td>chr7:NC_000007.14:g.99762186C>A</td><td>rs756833413</td><td>p.A370S</td><td>*1:C</td><td>C|C</td></tr>
<tr><td>chr7:NC_000007.14:g.99762177G>A</td><td>rs12721629</td><td>p.L373F</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99762047G>A</td><td>rs4986909</td><td>p.P416L</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99760956T>C</td><td>rs774109750</td><td>p.I427V</td><td>*1:T</td><td>T|T</td></tr>
<tr><td>chr7:NC_000007.14:g.99760901A>G</td><td>rs4986910</td><td>p.M445T</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99760836G>A</td><td>rs4986913</td><td>p.P467S</td><td>*1:G</td><td>G|G</td></tr>
<tr><td>chr7:NC_000007.14:g.99758188dup</td><td>rs67666821</td><td>p.P488fs</td><td>*1:T</td><td>Missing</td></tr>
</table>
<h3><b>CYP3A5: *3/*3</b></h3>
<table id="customer_table" border="1" cellspacing="0">
<tr><th>Position</th><th width="120px">rsID</th><th width="200px">Effect on Protein</th><th width="275px">Definition of Alleles</th><th width="200px">Detected Alleles</th></tr>
<tr><td>chr7:NC_000007.14:g.99652771dup</td><td>rs41303343</td><td>p.T346fs</td><td>*3:A</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99676198G>A</td><td>rs55817950</td><td>p.R28C</td><td>*3:G</td><td>Missing</td></tr>
<tr><td>chr7:NC_000007.14:g.99665212C>T</td><td>rs10264272</td><td>splicing defect</td><td>*3:C</td><td>C|C</td></tr>
<tr><td>chr7:NC_000007.14:g.99672916T>C</td><td>rs776746</td><td>splicing defect</td><td>*3:C</td><td>C|C</td></tr>
<tr><td>chr7:NC_000007.14:g.99660516C>T</td><td>rs28383479</td><td>p.A337T</td><td>*3:C</td><td>Missing</td></tr>
</table>
<h3><b>CYP4F2: *1/*1</b></h3>
<table id="customer_table" border="1" cellspacing="0">
<tr><th>Position</th><th width="120px">rsID</th><th width="200px">Effect on Protein</th><th width="275px">Definition of Alleles</th><th width="200px">Detected Alleles</th></tr>
<tr><td>chr19:NC_000019.10:g.15897578A>C</td><td>rs3093105</td><td>p.W12G</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.15879621C>T</td><td>rs2108622</td><td>p.V433M</td><td>*1:C</td><td>Missing</td></tr>
</table>
<h3><b>DPYD: Reference/c.85T>C (*9A)</b></h3>
<table id="customer_table" border="1" cellspacing="0">
<tr><th>Position</th><th width="120px">rsID</th><th width="200px">Effect on Protein</th><th width="275px">Definition of Alleles</th><th width="200px">Detected Alleles</th></tr>
<tr><td>chr1:NC_000001.11:g.97740411ATGA[1]</td><td>rs72549309</td><td></td><td>c.85T>C (*9A):ATGA(2); Reference:ATGA(2)</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97450067del</td><td>rs72549303</td><td>p.P633Qfs</td><td>c.85T>C (*9A):G; Reference:G</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97699399T>C</td><td>rs72549307</td><td>p.Y211C</td><td>c.85T>C (*9A):T; Reference:T</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97691776G>A</td><td>rs1801266</td><td>p.R235W</td><td>c.85T>C (*9A):G; Reference:G</td><td>G|G</td></tr>
<tr><td>chr1:NC_000001.11:g.97679170T>C</td><td>rs45589337</td><td>p.K259E</td><td>c.85T>C (*9A):T; Reference:T</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97595149T>C</td><td>rs146356975</td><td>p.K290E</td><td>c.85T>C (*9A):T; Reference:T</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97595088A>G</td><td>rs150437414</td><td>p.L310S</td><td>c.85T>C (*9A):A; Reference:A</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97595083G>A</td><td>rs145112791</td><td>p.L312F</td><td>c.85T>C (*9A):G; Reference:G</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97593379C>T</td><td>rs201018345</td><td>p.A323T</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97593343C>A</td><td>rs72549306</td><td>p.V335L</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97573839A>T</td><td>rs200064537</td><td>p.N420K</td><td>c.85T>C (*9A):A; Reference:A</td><td>A|A</td></tr>
<tr><td>chr1:NC_000001.11:g.97373629C>A</td><td>rs138545885</td><td>p.A664S</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97593289G>A</td><td>rs143154602</td><td>p.R353C</td><td>c.85T>C (*9A):G; Reference:G</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97593238T>C</td><td>rs72549305</td><td>p.I370V</td><td>c.85T>C (*9A):T; Reference:T</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97699533C>T</td><td>rs139834141</td><td>p.M166I</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97699506C>T</td><td>rs6670886</td><td>p.S175S</td><td>c.85T>C (*9A):C; Reference:C</td><td>C|C</td></tr>
<tr><td>chr1:NC_000001.11:g.97579893G>C</td><td>rs75017182</td><td></td><td>c.85T>C (*9A):G; Reference:G</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97699474T>C</td><td>rs115232898</td><td>p.Y186C</td><td>c.85T>C (*9A):T; Reference:T</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97573943C>A</td><td>rs78060119</td><td>p.E386X</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97573918C>A</td><td>rs143815742</td><td>p.R394L</td><td>c.85T>C (*9A):C; Reference:C</td><td>C|C</td></tr>
<tr><td>chr1:NC_000001.11:g.97573881C>T</td><td>rs61622928</td><td>p.M406I</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97573863C>T</td><td>rs56038477</td><td></td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97883329A>G</td><td>rs1801265</td><td>p.C29R</td><td>c.85T>C (*9A):G; Reference:A</td><td>A|G</td></tr>
<tr><td>chr1:NC_000001.11:g.97573821C>A</td><td>rs764666241</td><td>p.M426I</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97573805C>T</td><td>rs142512579</td><td>p.D432N</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97573785A>C</td><td>rs186169810</td><td>p.F438L</td><td>c.85T>C (*9A):A; Reference:A</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97549735G>A</td><td>rs72975710</td><td>p.A450V</td><td>c.85T>C (*9A):G; Reference:G</td><td>G|G</td></tr>
<tr><td>chr1:NC_000001.11:g.97549726G>C</td><td>rs144395748</td><td>p.P453R</td><td>c.85T>C (*9A):G; Reference:G</td><td>G|G</td></tr>
<tr><td>chr1:NC_000001.11:g.97549713G>A</td><td>rs57918000</td><td>p.N457N</td><td>c.85T>C (*9A):G; Reference:G</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97549681G>T</td><td>rs199549923</td><td>p.T468N</td><td>c.85T>C (*9A):G; Reference:G</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97515923C>T</td><td>rs148994843</td><td>p.V515I</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97549609G>A</td><td>rs72549304</td><td>p.S492L</td><td>c.85T>C (*9A):G; Reference:G</td><td>G|G</td></tr>
<tr><td>chr1:NC_000001.11:g.97549600T>C</td><td>rs111858276</td><td>p.D495G</td><td>c.85T>C (*9A):T; Reference:T</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97549565C>T</td><td>rs138391898</td><td>p.V507I</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97515889G>C</td><td>rs190951787</td><td>p.T526S</td><td>c.85T>C (*9A):G; Reference:G</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97515865C>T</td><td>rs1801158</td><td>p.S534N</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97515851C>T</td><td>rs142619737</td><td>p.G539R</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97515839T>C</td><td>rs1801159</td><td>p.I543V</td><td>c.85T>C (*9A):T; Reference:T</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97515787A>C</td><td>rs55886062</td><td>p.I560S</td><td>c.85T>C (*9A):A; Reference:A</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97515784C>A</td><td>rs201615754</td><td>p.R561L</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97450190G>A</td><td>rs59086055</td><td>p.R592W</td><td>c.85T>C (*9A):G; Reference:G</td><td>G|G</td></tr>
<tr><td>chr1:NC_000001.11:g.97450189C>T</td><td>rs138616379</td><td>p.R592Q</td><td>c.85T>C (*9A):C; Reference:C</td><td>C|C</td></tr>
<tr><td>chr1:NC_000001.11:g.97450187C>T</td><td>rs145773863</td><td>p.G593R</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97450168A>G</td><td>rs147601618</td><td>p.M599T</td><td>c.85T>C (*9A):A; Reference:A</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97450059G>C</td><td>rs3918289</td><td>p.N635K</td><td>c.85T>C (*9A):G; Reference:G</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97450058C>T</td><td>rs3918290</td><td>splicing defect</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97382461T>G</td><td>rs55971861</td><td>p.I636L</td><td>c.85T>C (*9A):T; Reference:T</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97373598C>T</td><td>rs137999090</td><td>p.G674D</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97306195C>T</td><td>rs145548112</td><td>p.A721T</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97305372G>A</td><td>rs146529561</td><td>p.A729V</td><td>c.85T>C (*9A):G; Reference:G</td><td>G|G</td></tr>
<tr><td>chr1:NC_000001.11:g.97305364C>T</td><td>rs1801160</td><td>p.V732I</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97305363A>C</td><td>rs60511679</td><td>p.V732G</td><td>c.85T>C (*9A):A; Reference:A</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97305279G>A</td><td>rs112766203</td><td>p.T760I</td><td>c.85T>C (*9A):G; Reference:G</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97234991G>T</td><td>rs56005131</td><td>p.T768K</td><td>c.85T>C (*9A):G; Reference:G</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97234958G>T</td><td>rs199634007</td><td>p.T779N</td><td>c.85T>C (*9A):G; Reference:G</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97193209C>T</td><td>rs200687447</td><td>p.E828K</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97193109T>C</td><td>rs60139309</td><td>p.K861R</td><td>c.85T>C (*9A):T; Reference:T</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97098632T>G</td><td>rs201035051</td><td>p.K875Q</td><td>c.85T>C (*9A):T; Reference:T</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97079077G>A</td><td>rs202144771</td><td>p.L993F</td><td>c.85T>C (*9A):G; Reference:G</td><td>G|G</td></tr>
<tr><td>chr1:NC_000001.11:g.97740400C>T</td><td>rs150385342</td><td>p.A105T</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97079076A>C</td><td>rs139459586</td><td>p.L993R</td><td>c.85T>C (*9A):A; Reference:A</td><td>A|A</td></tr>
<tr><td>chr1:NC_000001.11:g.97079071C>A</td><td>rs1801268</td><td>p.V995F</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97079005C>T</td><td>rs140114515</td><td>p.V1017I</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97078993C>G</td><td>rs148799944</td><td>p.V1021L</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97078987G>T</td><td>rs114096998</td><td>p.P1023T</td><td>c.85T>C (*9A):G; Reference:G</td><td>G|G</td></tr>
<tr><td>chr1:NC_000001.11:g.97883368G>C</td><td>rs150036960</td><td>p.L16V</td><td>c.85T>C (*9A):G; Reference:G</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97883353G>A</td><td>rs72549310</td><td>p.R21X</td><td>c.85T>C (*9A):G; Reference:G</td><td>G|G</td></tr>
<tr><td>chr1:NC_000001.11:g.97883352C>T</td><td>rs80081766</td><td>p.R21Q</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97721650T>C</td><td>rs141462178</td><td>p.M115V</td><td>c.85T>C (*9A):T; Reference:T</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97721542T>C</td><td>rs200562975</td><td>p.N151D</td><td>c.85T>C (*9A):T; Reference:T</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97699535T>C</td><td>rs2297595</td><td>p.M166V</td><td>c.85T>C (*9A):T; Reference:T</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97593322C>T</td><td>rs183385770</td><td>p.D342N</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97079121T>C</td><td>rs72547601</td><td>p.H978R</td><td>c.85T>C (*9A):T; Reference:T</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97450068A>G</td><td>rs17376848</td><td>p.F632F</td><td>c.85T>C (*9A):A; Reference:A</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97098616C>A</td><td>rs55674432</td><td>p.G880V</td><td>c.85T>C (*9A):C; Reference:C</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97098599G>A</td><td>rs147545709</td><td>p.R886C</td><td>c.85T>C (*9A):G; Reference:G</td><td>G|G</td></tr>
<tr><td>chr1:NC_000001.11:g.97098598C>T</td><td>rs1801267</td><td>p.R886H</td><td>c.85T>C (*9A):C; Reference:C</td><td>C|C</td></tr>
<tr><td>chr1:NC_000001.11:g.97699430T>G</td><td>rs72549308</td><td>p.S201R</td><td>c.85T>C (*9A):T; Reference:T</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97573919G>A</td><td>rs140602333</td><td>p.R394W</td><td>c.85T>C (*9A):G; Reference:G</td><td>G|G</td></tr>
<tr><td>chr1:NC_000001.11:g.97082391T>A</td><td>rs67376798</td><td>p.D949V</td><td>c.85T>C (*9A):T; Reference:T</td><td>T|T</td></tr>
<tr><td>chr1:NC_000001.11:g.97082365T>C</td><td>rs141044036</td><td>p.K958E</td><td>c.85T>C (*9A):T; Reference:T</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97079139T>C</td><td>rs145529148</td><td>p.Q972R</td><td>c.85T>C (*9A):T; Reference:T</td><td>Missing</td></tr>
<tr><td>chr1:NC_000001.11:g.97079133T>A</td><td>rs72547602</td><td>p.D974V</td><td>c.85T>C (*9A):T; Reference:T</td><td>Missing</td></tr>
</table>
<h3><b>G6PD: B (wildtype)/B (wildtype)</b></h3>
<table id="customer_table" border="1" cellspacing="0">
<tr><th>Position</th><th width="120px">rsID</th><th width="200px">Effect on Protein</th><th width="275px">Definition of Alleles</th><th width="200px">Detected Alleles</th></tr>
<tr><td>chrX:NC_000023.11:g.154532389C>T</td><td>rs137852324</td><td>p.R454H</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532279C>G</td><td></td><td>p.D456H</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532278T>A</td><td></td><td>p.D456V</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532269C>A/G</td><td>rs72554665</td><td>p.R459L/P</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535336G>C</td><td>rs267606835</td><td>p.S106C</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535330A>T</td><td></td><td>p.V108E</td><td>B (wildtype):A</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535316C>T</td><td>rs5030870</td><td>p.D113N</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535301A>G</td><td></td><td>p.Y118H</td><td>B (wildtype):A</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535278C>A</td><td></td><td>p.M125I</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535247G>A</td><td></td><td>p.R136C</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535244G>A</td><td></td><td>p.L137F</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535211C>T</td><td></td><td>p.E148K</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535190G>C</td><td></td><td>p.H155D</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535187C>T</td><td>rs137852313</td><td>p.E156K</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154536035G>A</td><td></td><td>p.R57W</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154536034C>T</td><td></td><td>p.R57E</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154536032C>T</td><td>rs137852315</td><td>p.D58N</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533029A>G</td><td>rs137852347</td><td>p.Y322H</td><td>B (wildtype):A</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154546051_154546053delGAT</td><td>rs137852338</td><td>p.I35del</td><td>B (wildtype):GAT</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154536169C>T</td><td></td><td>p.A44T</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154536022_154536024delAGA</td><td></td><td>p.L61del</td><td>B (wildtype):AGA</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534465A>G</td><td>rs137852343</td><td>p.F173L</td><td>B (wildtype):A</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533615C>G</td><td></td><td>p.K275N</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533064C>T</td><td></td><td>p.G310E</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532722C>T</td><td>rs371489738</td><td>p.G378S</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532625C>T/G</td><td>rs137852336</td><td>p.G410D/A</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532058_154532060delTTC</td><td></td><td>p.K497del</td><td>B (wildtype):TTC</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154546131G>A</td><td></td><td>p.R9W</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154546122C>A</td><td></td><td>p.V12L</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154546116C>T</td><td></td><td>p.G14R</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154546061T>C</td><td>rs137852340</td><td>p.H32R</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154546057T>C</td><td></td><td>p.I33M</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154546046A>G</td><td></td><td>p.M37T</td><td>B (wildtype):A</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534345C>A</td><td>rs137852326</td><td>p.V213L</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534125C>T/A</td><td>rs137852328</td><td>p.R227Q/L</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535176C>G</td><td>rs370918918</td><td>p.M159I</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534489T>C</td><td>rs137852331</td><td>p.N165D</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534486G>A</td><td></td><td>p.R166C</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534468G>A</td><td></td><td>p.P172S</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534463G>C</td><td></td><td>p.F173L</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534455T>C</td><td></td><td>p.D176G</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534447T>A</td><td></td><td>p.S179C</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534438G>A</td><td>rs267606836</td><td>p.R182W</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534419_154534421delGAG</td><td></td><td>p.S188del</td><td>B (wildtype):GAG</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534419G>A</td><td>rs5030868</td><td>p.S188F</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534102G>A</td><td>rs782757170</td><td>p.L235F</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534092T>C</td><td></td><td>p.K238R</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534036G>C</td><td></td><td>p.R257G</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533634C>T</td><td>rs137852346</td><td>p.C269Y</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533629C>G</td><td></td><td>p.V271L</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533620C>T</td><td></td><td>p.E274K</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533619T>A</td><td></td><td>p.E274V</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533614G>A</td><td></td><td>p.P276S</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533608A>G</td><td></td><td>p.S278P</td><td>B (wildtype):A</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533607G>A</td><td></td><td>p.S278F</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533605T>C/A</td><td></td><td>p.T279A/S</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533596C>A/G</td><td>rs137852318</td><td>p.D282H/Y</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533592T>C</td><td></td><td>p.D283G</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533591G>T</td><td></td><td>p.D283E</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533589A>G</td><td></td><td>p.V284A</td><td>B (wildtype):A</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533587G>A</td><td></td><td>p.R285C</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533586C>T</td><td>rs74575103</td><td>p.R285H</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533122C>T</td><td>rs137852327</td><td>p.V291M</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533083C>A</td><td></td><td>p.V303F</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533077C>T</td><td></td><td>p.G306S</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533072C>G</td><td></td><td>p.Q307H</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154536168G>C</td><td>rs78478128</td><td>p.A44G</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154536156A>G</td><td>rs76645461</td><td>p.I48T</td><td>B (wildtype):A</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154536151G>A</td><td></td><td>p.P50S</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154536025A>G</td><td></td><td>p.L60P</td><td>B (wildtype):A</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154536019G>A/T</td><td></td><td>p.P62L/H</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154536008A>T</td><td></td><td>p.P66I</td><td>B (wildtype):A</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154536002C>T</td><td>rs1050828</td><td>p.V68M</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535996A>G</td><td>rs137852349</td><td>p.Y70H</td><td>B (wildtype):A</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535995T>C</td><td>rs782090947</td><td>p.Y70C</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535980A>G</td><td></td><td>p.L75P</td><td>B (wildtype):A</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535963G>A</td><td>rs138687036</td><td>p.R81C</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535962C>T</td><td>rs782308266</td><td>p.R81H</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535379G>A</td><td></td><td>p.P92S</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535342C>T</td><td>rs181277621</td><td>p.R104H</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535277T>C</td><td>rs1050829</td><td>p.N126D</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535274C>A</td><td></td><td>p.A127S</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535270A>C/G</td><td>rs78365220</td><td>p.L128R/P</td><td>B (wildtype):A</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535269G>A</td><td></td><td>p.L128L</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535261C>A</td><td></td><td>p.G131V</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535249T>G</td><td>rs782322505</td><td>p.N135T</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535180C>T</td><td>rs782487723</td><td>p.C158Y</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534495C>T</td><td>rs137852314</td><td>p.G163S</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534494C>T</td><td></td><td>p.G163D</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534485C>T</td><td></td><td>p.R166H</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534409G>C</td><td></td><td>p.F191L</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534390G>A</td><td>rs137852330</td><td>p.R198C</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534389C>T/G</td><td>rs137852332</td><td>p.R198H/P</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534387T>C</td><td>rs781865768</td><td>p.I199V</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534348T>C</td><td>rs782754619</td><td>p.M212V</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534157A>C</td><td>rs137852319</td><td>p.F216L</td><td>B (wildtype):A</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534126G>A</td><td></td><td>p.R227W</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534120_154534122delTGT</td><td></td><td>p.N229del</td><td>B (wildtype):TGT</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534110C>T</td><td></td><td>p.C232Y</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532715A>G</td><td></td><td>p.I380T</td><td>B (wildtype):A</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532713A>G</td><td></td><td>p.F381L</td><td>B (wildtype):A</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532701A>G</td><td>rs137852322</td><td>p.C385R</td><td>B (wildtype):A</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533004C>T</td><td></td><td>p.R330H</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532991_154532993delGGT</td><td></td><td>p.T334del</td><td>B (wildtype):GGT</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532990C>T</td><td>rs5030869</td><td>p.A335T</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532989G>T</td><td></td><td>p.A335D</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532700C>A</td><td></td><td>p.C385F</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532772G>A</td><td>rs137852345</td><td>p.A361V</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532699G>C</td><td></td><td>p.C385W</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532698T>C</td><td>rs137852320</td><td>p.K386E</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532695G>A</td><td>rs137852334</td><td>p.R387C</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532694C>T</td><td>rs137852321</td><td>p.R387H</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532692T>C</td><td></td><td>p.N388D</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532688T>C</td><td></td><td>p.E389G</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532679A>G</td><td></td><td>p.I392T</td><td>B (wildtype):A</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532677G>C</td><td></td><td>p.R393G</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532676C>T</td><td>rs137852316</td><td>p.R393H</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532674C>G</td><td>rs137852335</td><td>p.V394L</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532667G>A</td><td></td><td>p.P396L</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532662C>T</td><td>rs137852325</td><td>p.E398K</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532661T>C</td><td></td><td>p.E398G</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532649G>T</td><td></td><td>p.T402N</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532639C>T</td><td></td><td>p.M405I</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532634T>G</td><td></td><td>p.K407T</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532629G>A</td><td></td><td>p.P409S</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532628G>C</td><td></td><td>p.P409R</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532626C>A</td><td>rs137852323</td><td>p.G410C</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532623T>C</td><td></td><td>p.M411V</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532608C>T</td><td></td><td>p.E416K</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532590G>C</td><td></td><td>p.L422V</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532570G>T</td><td></td><td>p.Y428X</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532459C>T</td><td>rs782098548</td><td>p.V431M</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532458A>C</td><td></td><td>p.V431G</td><td>B (wildtype):A</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532439G>A</td><td>rs2230037</td><td>p.Y437Y</td><td>B (wildtype):G</td><td>G|G</td></tr>
<tr><td>chrX:NC_000023.11:g.154532434C>G</td><td>rs137852337</td><td>p.Arg439Pro</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532432G>A</td><td></td><td>p.L440F</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532411C>T</td><td>rs137852317</td><td>p.G447R</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532408T>C</td><td></td><td>p.S448G</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532403C>G</td><td></td><td>p.Q449H</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532392A>T</td><td></td><td>p.V453E</td><td>B (wildtype):A</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532390G>A</td><td>rs398123546</td><td>p.R454C</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532265C>G</td><td></td><td>p.E460D</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532257C>T</td><td>rs72554664</td><td>p.R463H</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532245G>C</td><td>rs137852344</td><td>p.P467R</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532231T>G</td><td></td><td>p.I472L</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532203G>C</td><td>rs137852348</td><td>p.P481R</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532086C>T</td><td></td><td>p.G488S</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532085C>A</td><td></td><td>p.G488V</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532082G>A</td><td></td><td>p.P489L</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532046A>C</td><td></td><td>p.F501C</td><td>B (wildtype):A</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533044C>T</td><td>rs137852339</td><td>p.E317K</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533016G>T</td><td></td><td>p.P326H</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532987T>C</td><td></td><td>p.T336A</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532969G>A</td><td>rs137852342</td><td>p.L342F</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532956T>A</td><td>rs398123544</td><td>p.N346I</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532945C>G</td><td>rs34193178</td><td>p.D350H</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532802C>A</td><td></td><td>p.G351V</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532797G>A</td><td>rs137852333</td><td>p.P353S</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532773C>T</td><td></td><td>p.A361T</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532765G>C/T</td><td>rs137852329</td><td>p.N363K</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532758T>C</td><td></td><td>p.K366E</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532716T>C</td><td></td><td>p.I380V</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532258G>T/A</td><td></td><td>p.R463S/C</td><td>B (wildtype):G</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532264C>T</td><td>rs782608284</td><td>p.A461T</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154536045C>G</td><td></td><td>p.W53C</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154535370_154535372delTCT</td><td></td><td>p.K95del</td><td>B (wildtype):TCT</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534440T>A</td><td>rs5030872</td><td>p.D181V</td><td>B (wildtype):T</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154534076_154534081delAGTGCC</td><td></td><td>p.G242_T243del</td><td>B (wildtype):AGTGCC</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533015_154533038delGGGGTCGTCCAGGTACCCTTTGGT</td><td></td><td>p.T319_P326del</td><td>B (wildtype):GGGGTCGTCCAGGTACCCTTTGGT</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533031C>T</td><td></td><td>p.G321E</td><td>B (wildtype):C</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154533025A>G</td><td>rs76723693</td><td>p.L323P</td><td>B (wildtype):A</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532753_154532770delGGCCTTGCGCTCGTTCAG</td><td></td><td>p.L362_A367del</td><td>B (wildtype):GGCCTTGCGCTCGTTCAG</td><td>Missing</td></tr>
<tr><td>chrX:NC_000023.11:g.154532083G>A</td><td></td><td>p.P489S</td><td>B (wildtype):G</td><td>Missing</td></tr>
</table>
<h3><b>MT-RNR1: Reference/Reference</b></h3>
<table id="customer_table" border="1" cellspacing="0">
<tr><th>Position</th><th width="120px">rsID</th><th width="200px">Effect on Protein</th><th width="275px">Definition of Alleles</th><th width="200px">Detected Alleles</th></tr>
<tr><td>chrM:NC_012920.1:m.807A>C; m.807A>G</td><td></td><td></td><td>Reference:A</td><td>Missing</td></tr>
<tr><td>chrM:NC_012920.1:m.960delC</td><td></td><td></td><td>Reference:C</td><td>Missing</td></tr>
<tr><td>chrM:NC_012920.1:m.961T>G</td><td>rs3888511</td><td></td><td>Reference:T</td><td>Missing</td></tr>
<tr><td>chrM:NC_012920.1:m.961delT; m.961delTinsC(n)</td><td>rs1556422499</td><td></td><td>Reference:T</td><td>Missing</td></tr>
<tr><td>chrM:NC_012920.1:m.663A>G</td><td>rs56489998</td><td></td><td>Reference:A</td><td>Missing</td></tr>
<tr><td>chrM:NC_012920.1:m.669T>C</td><td></td><td></td><td>Reference:T</td><td>Missing</td></tr>
<tr><td>chrM:NC_012920.1:m.747A>G</td><td></td><td></td><td>Reference:A</td><td>Missing</td></tr>
<tr><td>chrM:NC_012920.1:m.786G>A</td><td></td><td></td><td>Reference:G</td><td>Missing</td></tr>
<tr><td>chrM:NC_012920.1:m.827A>G</td><td>rs28358569</td><td></td><td>Reference:A</td><td>Missing</td></tr>
<tr><td>chrM:NC_012920.1:m.839A>G</td><td></td><td></td><td>Reference:A</td><td>Missing</td></tr>
<tr><td>chrM:NC_012920.1:m.896A>G</td><td></td><td></td><td>Reference:A</td><td>Missing</td></tr>
<tr><td>chrM:NC_012920.1:m.930A>G</td><td></td><td></td><td>Reference:A</td><td>Missing</td></tr>
<tr><td>chrM:NC_012920.1:m.951G>A</td><td>rs200887992</td><td></td><td>Reference:G</td><td>Missing</td></tr>
<tr><td>chrM:NC_012920.1:m.988G>A</td><td></td><td></td><td>Reference:G</td><td>Missing</td></tr>
<tr><td>chrM:NC_012920.1:m.1095T>C</td><td>rs267606618</td><td></td><td>Reference:T</td><td>Missing</td></tr>
<tr><td>chrM:NC_012920.1:m.1189T>C</td><td>rs28358571</td><td></td><td>Reference:T</td><td>Missing</td></tr>
<tr><td>chrM:NC_012920.1:m.1243T>C</td><td>rs28358572</td><td></td><td>Reference:T</td><td>Missing</td></tr>
<tr><td>chrM:NC_012920.1:m.1494C>T</td><td>rs267606619</td><td></td><td>Reference:C</td><td>Missing</td></tr>
<tr><td>chrM:NC_012920.1:m.1520T>C</td><td></td><td></td><td>Reference:T</td><td>Missing</td></tr>
<tr><td>chrM:NC_012920.1:m.1537C>T</td><td></td><td></td><td>Reference:C</td><td>Missing</td></tr>
<tr><td>chrM:NC_012920.1:m.1555A>G</td><td>rs267606617</td><td></td><td>Reference:A</td><td>Missing</td></tr>
<tr><td>chrM:NC_012920.1:m.1556C>T</td><td></td><td></td><td>Reference:C</td><td>Missing</td></tr>
</table>
<h3><b>NUDT15: *1/*1</b></h3>
<table id="customer_table" border="1" cellspacing="0">
<tr><th>Position</th><th width="120px">rsID</th><th width="200px">Effect on Protein</th><th width="275px">Definition of Alleles</th><th width="200px">Detected Alleles</th></tr>
<tr><td>chr13:NC_000013.11:g.48037826_48037827insCGGG</td><td>rs777311140</td><td>p.C28fs</td><td>*1:del</td><td>Missing</td></tr>
<tr><td>chr13:NC_000013.11:g.48037784GAGTCG[2]; g.48037784GAGTCG[4]</td><td>rs746071566</td><td>p.del17_18GV; p.V18_V19insGV</td><td>*1:GAGTCG(3)</td><td>Missing</td></tr>
<tr><td>chr13:NC_000013.11:g.48040982del</td><td>rs1457579126</td><td>p.N74fs</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr13:NC_000013.11:g.48041104dup</td><td>rs761191455</td><td>p.E115fs</td><td>*1:G</td><td>G|G</td></tr>
<tr><td>chr13:NC_000013.11:g.48037847G>C</td><td>rs766023281</td><td>p.R34T</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr13:NC_000013.11:g.48037748T>C</td><td>rs769369441</td><td>p.M1T</td><td>*1:T</td><td>Missing</td></tr>
<tr><td>chr13:NC_000013.11:g.48037749G>C</td><td></td><td>p.M1I</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr13:NC_000013.11:g.48037798G>A</td><td>rs186364861</td><td>p.V18I</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr13:NC_000013.11:g.48037849A>G</td><td></td><td>p.K35E</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr13:NC_000013.11:g.48037885G>A</td><td>rs1950545307</td><td>p.G47R</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr13:NC_000013.11:g.48037902C>G</td><td>rs149436418</td><td>p.F52L</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr13:NC_000013.11:g.48041113G>T</td><td>rs1368252918</td><td>p.E118X</td><td>*1:G</td><td>G|G</td></tr>
<tr><td>chr13:NC_000013.11:g.48045690C>G</td><td>rs768324690</td><td>p.P129R</td><td>*1:C</td><td>C|C</td></tr>
<tr><td>chr13:NC_000013.11:g.48045719C>T</td><td>rs116855232</td><td>p.R139C</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr13:NC_000013.11:g.48045720G>A</td><td>rs147390019</td><td>p.R139H</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr13:NC_000013.11:g.48045771T>A</td><td>rs139551410</td><td>p.L156Q</td><td>*1:T</td><td>Missing</td></tr>
<tr><td>chr13:NC_000013.11:g.48037834C>T</td><td>rs1202487323</td><td>p.L30V</td><td>*1:C</td><td>Missing</td></tr>
</table>
<h3><b>IFNL3: C/T</b></h3>
<table id="customer_table" border="1" cellspacing="0">
<tr><th>Position</th><th width="120px">rsID</th><th width="200px">Effect on Protein</th><th width="275px">Definition of Alleles</th><th width="200px">Detected Alleles</th></tr>
<tr><td>chr19:NC_000019.10:g.39248147C>T</td><td>rs12979860</td><td></td><td>C:C; T:T</td><td>C|T</td></tr>
</table>
<h3><b>RYR1: Reference/Reference</b></h3>
<table id="customer_table" border="1" cellspacing="0">
<tr><th>Position</th><th width="120px">rsID</th><th width="200px">Effect on Protein</th><th width="275px">Definition of Alleles</th><th width="200px">Detected Alleles</th></tr>
<tr><td>chr19:NC_000019.10:g.38455463G>A</td><td>rs111888148</td><td>p.R530H</td><td>Reference:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38457546G>T</td><td>rs193922772</td><td>p.R614L</td><td>Reference:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38448712G>A; g.38448712G>C</td><td>rs121918592</td><td>p.G341R</td><td>Reference:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38451850C>G</td><td>rs118192116</td><td>p.I403M</td><td>Reference:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38455472G>A</td><td>rs144336148</td><td>p.R533H</td><td>Reference:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38455528C>T</td><td>rs193922770</td><td>p.R552W</td><td>Reference:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38446710G>C; g.38446710G>A</td><td>rs1801086</td><td>p.G248R</td><td>Reference:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38448673C>T</td><td>rs193922762</td><td>p.R328W</td><td>Reference:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38451842C>T</td><td>rs193922764</td><td>p.R401C</td><td>Reference:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38455359A>C</td><td>rs118192162</td><td>p.Y522S</td><td>Reference:A</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38455471C>T</td><td>rs193922768</td><td>p.R533C</td><td>Reference:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38457545C>T</td><td>rs118192172</td><td>p.R614C</td><td>Reference:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38494564C>T</td><td>rs118192175</td><td>p.R2163C</td><td>Reference:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38496283C>G; g.38496283C>T</td><td>rs118192177</td><td>p.T2206R; p.T2206M</td><td>Reference:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38499223G>A</td><td>rs112563513</td><td>p.R2336H</td><td>Reference:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38499646_38499648delGAG</td><td>rs121918596</td><td>p.E2348del</td><td>Reference:GAG</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38499655G>A</td><td>rs193922802</td><td>p.A2350T</td><td>Reference:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38499670C>T</td><td>rs193922803</td><td>p.R2355W</td><td>Reference:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38499731G>C</td><td>rs193922807</td><td>p.G2375A</td><td>Reference:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38499975G>A</td><td>rs193922809</td><td>p.A2428T</td><td>Reference:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38499993G>A</td><td>rs121918593</td><td>p.G2434R</td><td>Reference:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38499997G>A</td><td>rs28933396</td><td>p.R2435H</td><td>Reference:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38500636C>T</td><td>rs118192124</td><td>p.R2452W</td><td>Reference:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38500642C>T</td><td>rs193922816</td><td>p.R2454C</td><td>Reference:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38500643G>A</td><td>rs118192122</td><td>p.R2454H</td><td>Reference:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38500654C>T</td><td>rs28933397</td><td>p.R2458C</td><td>Reference:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38500655G>A</td><td>rs121918594</td><td>p.R2458H</td><td>Reference:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38500899G>A</td><td>rs193922818</td><td>p.R2508H</td><td>Reference:G</td><td>G|G</td></tr>
<tr><td>chr19:NC_000019.10:g.38512321G>A</td><td>rs193922832</td><td>p.E3104K</td><td>Reference:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38543832G>T</td><td>rs193922843</td><td>p.G3990V</td><td>Reference:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38580004A>G</td><td>rs118192167</td><td>p.Y4796C</td><td>Reference:A</td><td>A|A</td></tr>
<tr><td>chr19:NC_000019.10:g.38580094C>T</td><td>rs121918595</td><td>p.T4826I</td><td>Reference:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38580114C>T</td><td>rs193922876</td><td>p.H4833Y</td><td>Reference:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38580370C>G</td><td>rs193922878</td><td>p.L4838V</td><td>Reference:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38580403G>A</td><td>rs118192168</td><td>p.V4849I</td><td>Reference:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38580440G>A</td><td>rs63749869</td><td>p.R4861H</td><td>Reference:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38440802T>C</td><td>rs193922747</td><td>p.C35R</td><td>Reference:T</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38440829C>T</td><td>rs193922748</td><td>p.R44C</td><td>Reference:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38444211C>T</td><td>rs118192161</td><td>p.R163C</td><td>Reference:C</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38444212G>T</td><td>rs193922753</td><td>p.R163L</td><td>Reference:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38494565G>A</td><td>rs118192163</td><td>p.R2163H</td><td>Reference:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38494579G>A</td><td>rs118192176</td><td>p.V2168M</td><td>Reference:G</td><td>Missing</td></tr>
<tr><td>chr19:NC_000019.10:g.38500898C>T; g.38500898C>G</td><td>rs118192178</td><td>p.R2508C; p.R2508G</td><td>Reference:C</td><td>C|C</td></tr>
<tr><td>chr19:NC_000019.10:g.38584989T>C</td><td>rs118192170</td><td>p.I4898T</td><td>Reference:T</td><td>Missing</td></tr>
</table>
<h3><b>SLCO1B1: *1/*15</b></h3>
<table id="customer_table" border="1" cellspacing="0">
<tr><th>Position</th><th width="120px">rsID</th><th width="200px">Effect on Protein</th><th width="275px">Definition of Alleles</th><th width="200px">Detected Alleles</th></tr>
<tr><td>chr12:NC_000012.12:g.21172734C>T</td><td>rs139257324</td><td>p.R57W</td><td>*1:C; *15:C</td><td>Missing</td></tr>
<tr><td>chr12:NC_000012.12:g.21172776G>A</td><td>rs373327528</td><td>p.G71R</td><td>*1:G; *15:G</td><td>Missing</td></tr>
<tr><td>chr12:NC_000012.12:g.21172782T>C</td><td>rs56101265</td><td>p.F73L</td><td>*1:T; *15:T</td><td>T|T</td></tr>
<tr><td>chr12:NC_000012.12:g.21174595T>C</td><td>rs56061388</td><td>p.V82A</td><td>*1:T; *15:T</td><td>Missing</td></tr>
<tr><td>chr12:NC_000012.12:g.21176804A>G</td><td>rs2306283</td><td>p.N130D</td><td>*1:A; *15:G</td><td>A|G</td></tr>
<tr><td>chr12:NC_000012.12:g.21176868A>G</td><td>rs2306282</td><td>p.N151S</td><td>*1:A; *15:A</td><td>Missing</td></tr>
<tr><td>chr12:NC_000012.12:g.21176871G>A</td><td></td><td>p.R152L</td><td>*1:G; *15:G</td><td>Missing</td></tr>
<tr><td>chr12:NC_000012.12:g.21176879C>A</td><td>rs11045819</td><td>p.P155T</td><td>*1:C; *15:C</td><td>Missing</td></tr>
<tr><td>chr12:NC_000012.12:g.21176883A>G</td><td>rs72559745</td><td>p.E156G</td><td>*1:A; *15:A</td><td>Missing</td></tr>
<tr><td>chr12:NC_000012.12:g.21176898G>T</td><td>rs77271279</td><td>splicing defect</td><td>*1:G; *15:G</td><td>Missing</td></tr>
<tr><td>chr12:NC_000012.12:g.21178612A>G</td><td>rs141467543</td><td>p.Y173C</td><td>*1:A; *15:A</td><td>Missing</td></tr>
<tr><td>chr12:NC_000012.12:g.21178615T>C</td><td>rs4149056</td><td>p.V174A</td><td>*1:T; *15:C</td><td>T|C</td></tr>
<tr><td>chr12:NC_000012.12:g.21178957A>G</td><td>rs79135870</td><td>p.I222V</td><td>*1:A; *15:A</td><td>A|A</td></tr>
<tr><td>chr12:NC_000012.12:g.21196951A>G</td><td>rs11045852</td><td>p.I245V</td><td>*1:A; *15:A</td><td>Missing</td></tr>
<tr><td>chr12:NC_000012.12:g.21196975C>T</td><td>rs183501729</td><td>p.R253X</td><td>*1:C; *15:C</td><td>Missing</td></tr>
<tr><td>chr12:NC_000012.12:g.21196976G>A</td><td>rs11045853</td><td>p.R253Q</td><td>*1:G; *15:G</td><td>Missing</td></tr>
<tr><td>chr12:NC_000012.12:g.21200544C>G</td><td>rs72559747</td><td>p.P336R</td><td>*1:C; *15:C</td><td>Missing</td></tr>
<tr><td>chr12:NC_000012.12:g.21200595T>C</td><td>rs55901008</td><td>p.I353T</td><td>*1:T; *15:T</td><td>Missing</td></tr>
<tr><td>chr12:NC_000012.12:g.21202553T>G</td><td>rs1228465562</td><td>p.F400V</td><td>*1:T; *15:T</td><td>Missing</td></tr>
<tr><td>chr12:NC_000012.12:g.21202555C>G</td><td>rs59113707</td><td>p.F400L</td><td>*1:C; *15:C</td><td>Missing</td></tr>
<tr><td>chr12:NC_000012.12:g.21202649A>G</td><td>rs56387224</td><td>p.N432D</td><td>*1:A; *15:A</td><td>Missing</td></tr>
<tr><td>chr12:NC_000012.12:g.21202664G>A</td><td>rs142965323</td><td>p.G437R</td><td>*1:G; *15:G</td><td>Missing</td></tr>
<tr><td>chr12:NC_000012.12:g.21205921A>G</td><td>rs72559748</td><td>p.D462G</td><td>*1:A; *15:A</td><td>Missing</td></tr>
<tr><td>chr12:NC_000012.12:g.21205999G>C</td><td>rs59502379</td><td>p.G488A</td><td>*1:G; *15:G</td><td>Missing</td></tr>
<tr><td>chr12:NC_000012.12:g.21206031A>G</td><td>rs74064213</td><td>p.I499V</td><td>*1:A; *15:A</td><td>Missing</td></tr>
<tr><td>chr12:NC_000012.12:g.21222355C>T</td><td>rs71581941</td><td>p.R580X</td><td>*1:C; *15:C</td><td>C|C</td></tr>
<tr><td>chr12:NC_000012.12:g.21239042A>C</td><td>rs34671512</td><td>p.L643F</td><td>*1:A; *15:A</td><td>A|A</td></tr>
<tr><td>chr12:NC_000012.12:g.21239077A>G</td><td>rs56199088</td><td>p.D655G</td><td>*1:A; *15:A</td><td>A|A</td></tr>
<tr><td>chr12:NC_000012.12:g.21239113A>G</td><td>rs55737008</td><td>p.E667G</td><td>*1:A; *15:A</td><td>Missing</td></tr>
<tr><td>chr12:NC_000012.12:g.21239145C>T</td><td>rs200995543</td><td>p.H678Y</td><td>*1:C; *15:C</td><td>Missing</td></tr>
<tr><td>chr12:NC_000012.12:g.21239158C>T</td><td>rs140790673</td><td>p.S682F</td><td>*1:C; *15:C</td><td>Missing</td></tr>
</table>
<h3><b>TPMT: *1/*1</b></h3>
<table id="customer_table" border="1" cellspacing="0">
<tr><th>Position</th><th width="120px">rsID</th><th width="200px">Effect on Protein</th><th width="275px">Definition of Alleles</th><th width="200px">Detected Alleles</th></tr>
<tr><td>chr6:NC_000006.12:g.18149127T>C</td><td>rs9333569</td><td>p.M1V</td><td>*1:T</td><td>T|T</td></tr>
<tr><td>chr6:NC_000006.12:g.18149126A>G</td><td>rs267607275</td><td>p.M1T</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18149045T>A</td><td>rs72552742</td><td>p.E28V</td><td>*1:T</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18149032_18149033insT</td><td>rs759836180</td><td>p.K32KfsX58</td><td>*1:del</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18149022C>T</td><td>rs750424422</td><td>p.G36S</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18149004G>C</td><td></td><td>p.Q42E</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18147910A>G</td><td>rs72552740</td><td>p.L49S</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18147856A>G</td><td></td><td>p.F67S</td><td>*1:A</td><td>A|A</td></tr>
<tr><td>chr6:NC_000006.12:g.18147851G>C</td><td>rs200591577</td><td>p.L69V</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18147845C>T</td><td>rs777686348</td><td>p.G71R</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18147838G>A</td><td>rs281874771</td><td>p.A73V</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18143724C>G</td><td>rs1800462</td><td>p.A80P</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18143718G>A</td><td>rs111901354</td><td>p.R82W</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18143700C>T</td><td>rs753545734</td><td>p.G88S</td><td>*1:C</td><td>C|C</td></tr>
<tr><td>chr6:NC_000006.12:g.18143643A>C</td><td></td><td>p.Y107D</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18143622C>T</td><td>rs115106679</td><td>p.E114K</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18143613C>G</td><td></td><td>p.G117R</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18143606T>G</td><td>rs151149760</td><td>p.K119T</td><td>*1:T</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18143597T>G</td><td></td><td>p.K122T</td><td>*1:T</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18139710G>A</td><td>rs200220210</td><td>p.S125L</td><td>*1:G</td><td>G|G</td></tr>
<tr><td>chr6:NC_000006.12:g.18139689C>T</td><td>rs72552738</td><td>p.C132Y</td><td>*1:C</td><td>C|C</td></tr>
<tr><td>chr6:NC_000006.12:g.18139027C>G</td><td>rs72552737</td><td>p.G144R</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18138997C>T</td><td>rs1800460</td><td>p.A154T</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18138970G>A</td><td>rs112339338</td><td>p.R163C</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18133890C>T</td><td>rs9333570</td><td></td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18133887T>C</td><td>rs201695576</td><td>p.Y166C</td><td>*1:T</td><td>T|T</td></tr>
<tr><td>chr6:NC_000006.12:g.18133884G>C</td><td>rs74423290</td><td>p.A167G</td><td>*1:G</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18133870A>G</td><td>rs772832951</td><td>p.S172P</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18133847C>A</td><td>rs6921269</td><td>p.Q179H</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18133845T>A</td><td>rs75543815</td><td>p.Y180F</td><td>*1:T</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18132163C>T</td><td></td><td>p.V199I</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18132147A>G</td><td>rs79901429</td><td>p.I204T</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18132136A>G</td><td>rs72556347</td><td>p.F208L</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18130781C>T</td><td>rs1800584</td><td></td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18130772A>G</td><td>rs377085266</td><td>p.C212R</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18130762C>T</td><td>rs56161402</td><td>p.R215H</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18130758A>T</td><td>rs398122996</td><td>p.C216X</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18130729C>T</td><td>rs139392616</td><td>p.R226Q</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18130725A>C</td><td>rs72552736</td><td>p.H227Q</td><td>*1:A</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18130694T>C</td><td>rs150900439</td><td>p.K238E</td><td>*1:T</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18130687T>C; g.18130687T>G</td><td>rs1142345</td><td>p.Y240C; p.Y240S</td><td>*1:T</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18143728C>A</td><td>rs1256618794</td><td>p.W78C</td><td>*1:C</td><td>Missing</td></tr>
<tr><td>chr6:NC_000006.12:g.18138969C>T; g.18138969C>G</td><td>rs144041067</td><td>p.R163H; p.R163P</td><td>*1:C</td><td>Missing</td></tr>
</table>
<h3><b>UGT1A1: *60/*80</b></h3>
<table id="customer_table" border="1" cellspacing="0">
<tr><th>Position</th><th width="120px">rsID</th><th width="200px">Effect on Protein</th><th width="275px">Definition of Alleles</th><th width="200px">Detected Alleles</th></tr>
<tr><td>chr2:NC_000002.12:g.233757013T>G</td><td>rs4124874</td><td> 5' Flanking</td><td>*60:G; *80:T</td><td>T|G</td></tr>
<tr><td>chr2:NC_000002.12:g.233759924C>T</td><td>rs887829</td><td>5' Flanking</td><td>*60:C; *80:T</td><td>C|T</td></tr>
<tr><td>chr2:NC_000002.12:g.233760235TA[6]; g.233760235TA[7]; g.233760235TA[8]; g.233760235TA[9]</td><td>rs3064744</td><td>5' Flanking</td><td>*60:TA(7); *80:TA(7)</td><td>TA(7)|TA(7)</td></tr>
<tr><td>chr2:NC_000002.12:g.233760498G>A</td><td>rs4148323</td><td>p.G71R</td><td>*60:G; *80:G</td><td>Missing</td></tr>
<tr><td>chr2:NC_000002.12:g.233760973C>A</td><td>rs35350960</td><td>p.P229Q</td><td>*60:C; *80:C</td><td>Missing</td></tr>
</table>
<h3><b>VKORC1: C/T</b></h3>
<table id="customer_table" border="1" cellspacing="0">
<tr><th>Position</th><th width="120px">rsID</th><th width="200px">Effect on Protein</th><th width="275px">Definition of Alleles</th><th width="200px">Detected Alleles</th></tr>
<tr><td>chr16:NC_000016.10:g.31096368C>T</td><td>rs9923231</td><td>5' region</td><td>C:C; T:T</td><td>C|T</td></tr>
</table>
<h2 id="pgx annotation"><b>PGx Annotation</b></h2>
<p class="main_lead">PAnno annotates PGx-related single-locus genotypes and predicted diplotypes using the knowledge from PharmGKB, which are the basis for calculating the PGx summary results.</p>
<table id="customer_table" border="1" cellspacing="0">
<tr><th width="60px"></th><th>Gene</th><th>Variant</th><th>Alleles</th><th>Drug</th><th>Evidence</th><th>Category</th><th>Function</th></tr>
<tr><td>1 <a href=https://www.pharmgkb.org/clinicalAnnotation/1450806874 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C19</td><td>*2</td><td>*2</td><td>lansoprazole</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>2 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183689931 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP3A4</td><td>*1</td><td>*1</td><td>tacrolimus</td><td>1B</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>3 <a href=https://www.pharmgkb.org/clinicalAnnotation/982047500 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C9</td><td>*1</td><td>*1</td><td>phenytoin</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>4 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183617103 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C19</td><td>*2</td><td>*2</td><td>imipramine</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>5 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183621987 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C19</td><td>*2</td><td>*2</td><td>trimipramine</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>6 <a href=https://www.pharmgkb.org/clinicalAnnotation/1043858794 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C19</td><td>*2</td><td>*2</td><td>clopidogrel</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>7 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183619004 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C19</td><td>*2</td><td>*2</td><td>sertraline</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>8 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183620386 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C19</td><td>*2</td><td>*2</td><td>citalopram</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>9 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183617854 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C19</td><td>*2</td><td>*2</td><td>doxepin</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>10 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183616699 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C19</td><td>*2</td><td>*2</td><td>clomipramine</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>11 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183617714 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C19</td><td>*2</td><td>*2</td><td>amitriptyline</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>12 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183630065 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C19</td><td>*2</td><td>*2</td><td>omeprazole</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>13 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183624491 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C19</td><td>*2</td><td>*2</td><td>pantoprazole</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>14 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183629373 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C19</td><td>*2</td><td>*2</td><td>rabeprazole</td><td>2A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>15 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451282740 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C19</td><td>*2</td><td>*2</td><td>escitalopram</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>16 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451231100 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C9</td><td>*1</td><td>*1</td><td>siponimod</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>17 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183689217 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C19</td><td>*2</td><td>*2</td><td>voriconazole</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>18 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451666660 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>ABCG2</td><td>rs2231142</td><td>GG</td><td>rosuvastatin</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>19 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451666740 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C9</td><td>*1</td><td>*1</td><td>fluvastatin</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>20 <a href=https://www.pharmgkb.org/clinicalAnnotation/1444842106 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C9</td><td>*1</td><td>*1</td><td>flurbiprofen</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>21 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183703296 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C9</td><td>*1</td><td>*1</td><td>lornoxicam</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>22 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451092460 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C9</td><td>*1</td><td>*1</td><td>tenoxicam</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>23 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451092541 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C9</td><td>*1</td><td>*1</td><td>piroxicam</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>24 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451092677 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C9</td><td>*1</td><td>*1</td><td>meloxicam</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>25 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451092720 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C9</td><td>*1</td><td>*1</td><td>ibuprofen</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>26 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451137080 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C19</td><td>*2</td><td>*2</td><td>dexlansoprazole</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>27 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451236700 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C9</td><td>*1</td><td>*1</td><td>celecoxib</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>28 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451147720 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP3A4</td><td>*1</td><td>*1</td><td>quetiapine</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>29 <a href=https://www.pharmgkb.org/clinicalAnnotation/827923032 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2B6</td><td>rs3745274</td><td>GT</td><td>efavirenz</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>30 <a href=https://www.pharmgkb.org/clinicalAnnotation/981202294 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2B6</td><td>rs3745274</td><td>GT</td><td>nevirapine</td><td>2A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>31 <a href=https://www.pharmgkb.org/clinicalAnnotation/981345293 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>SLCO1B1</td><td>rs4149056</td><td>CT</td><td>pravastatin</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>32 <a href=https://www.pharmgkb.org/clinicalAnnotation/981345350 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>SLCO1B1</td><td>rs4149056</td><td>CT</td><td>rosuvastatin</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>33 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451678112 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>SLCO1B1</td><td>rs4149056</td><td>CT</td><td>lovastatin</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>34 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451678112 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>SLCO1B1</td><td>rs4149056</td><td>CT</td><td>lovastatin acid</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>35 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451678210 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>SLCO1B1</td><td>rs4149056</td><td>CT</td><td>pitavastatin</td><td>1A</td><td>Metabolism/PK</td><td>Increased</td></tr>
<tr><td>36 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183630036 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C19</td><td>*2</td><td>*2</td><td>omeprazole</td><td>1A</td><td>Efficacy</td><td>Increased</td></tr>
<tr><td>37 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183624499 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C19</td><td>*2</td><td>*2</td><td>pantoprazole</td><td>1A</td><td>Efficacy</td><td>Increased</td></tr>
<tr><td>38 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183629796 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C19</td><td>*2</td><td>*2</td><td>lansoprazole</td><td>1A</td><td>Efficacy</td><td>Increased</td></tr>
<tr><td>39 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451282340 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C19</td><td>*2</td><td>*2</td><td>clopidogrel</td><td>1A</td><td>Efficacy</td><td>Increased</td></tr>
<tr><td>40 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451282440 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C19</td><td>*2</td><td>*2</td><td>clopidogrel</td><td>1A</td><td>Efficacy</td><td>Increased</td></tr>
<tr><td>41 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183492249 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>APOE</td><td>rs7412</td><td>CT</td><td>atorvastatin</td><td>2B</td><td>Efficacy</td><td>Increased</td></tr>
<tr><td>42 <a href=https://www.pharmgkb.org/clinicalAnnotation/655384621 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>KIF6</td><td>rs20455</td><td>AG</td><td>pravastatin</td><td>2B</td><td>Efficacy</td><td>Increased</td></tr>
<tr><td>43 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451282440 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C19</td><td>*2</td><td>*2</td><td>clopidogrel</td><td>1A</td><td>Toxicity</td><td>Increased</td></tr>
<tr><td>44 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451282840 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C19</td><td>*2</td><td>*2</td><td>citalopram</td><td>1A</td><td>Toxicity</td><td>Increased</td></tr>
<tr><td>45 <a href=https://www.pharmgkb.org/clinicalAnnotation/1449269910 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>VKORC1</td><td>rs9923231</td><td>CT</td><td>warfarin</td><td>2A</td><td>Toxicity</td><td>Increased</td></tr>
<tr><td>46 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447673005 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>VKORC1</td><td>rs9923231</td><td>CT</td><td>warfarin</td><td>1B</td><td>Toxicity</td><td>Increased</td></tr>
<tr><td>47 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451243676 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>VKORC1</td><td>rs9923231</td><td>CT</td><td>phenprocoumon</td><td>2A</td><td>Toxicity</td><td>Increased</td></tr>
<tr><td>48 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451357200 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>SLCO1B1</td><td>rs4149056</td><td>CT</td><td>rosuvastatin</td><td>1A</td><td>Toxicity</td><td>Increased</td></tr>
<tr><td>49 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451244720 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>SLCO1B1</td><td>rs4149056</td><td>CT</td><td>fluvastatin</td><td>1A</td><td>Toxicity</td><td>Increased</td></tr>
<tr><td>50 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451244740 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>SLCO1B1</td><td>rs4149056</td><td>CT</td><td>pravastatin</td><td>1A</td><td>Toxicity</td><td>Increased</td></tr>
<tr><td>51 <a href=https://www.pharmgkb.org/clinicalAnnotation/1043880818 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>SLCO1B1</td><td>rs4149056</td><td>CT</td><td>atorvastatin</td><td>1A</td><td>Toxicity</td><td>Increased</td></tr>
<tr><td>52 <a href=https://www.pharmgkb.org/clinicalAnnotation/655384011 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>SLCO1B1</td><td>rs4149056</td><td>CT</td><td>simvastatin</td><td>1A</td><td>Toxicity</td><td>Increased</td></tr>
<tr><td>53 <a href=https://www.pharmgkb.org/clinicalAnnotation/827923042 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2B6</td><td>rs3745274</td><td>GT</td><td>efavirenz</td><td>1A</td><td>Toxicity</td><td>Increased</td></tr>
<tr><td>54 <a href=https://www.pharmgkb.org/clinicalAnnotation/981345382 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>SLCO1B1</td><td>rs4149056</td><td>CT</td><td>hmg coa reductase inhibitors</td><td>2A</td><td>Toxicity</td><td>Increased</td></tr>
<tr><td>55 <a href=https://www.pharmgkb.org/clinicalAnnotation/1449269910 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>VKORC1</td><td>rs9923231</td><td>CT</td><td>warfarin</td><td>2A</td><td>Toxicity</td><td>Increased</td></tr>
<tr><td>56 <a href=https://www.pharmgkb.org/clinicalAnnotation/1446905691 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>ITPA</td><td>rs1127354</td><td>CC</td><td>peginterferon alfa-2b</td><td>2B</td><td>Toxicity</td><td>Increased</td></tr>
<tr><td>57 <a href=https://www.pharmgkb.org/clinicalAnnotation/1446905691 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>ITPA</td><td>rs1127354</td><td>CC</td><td>ribavirin</td><td>2B</td><td>Toxicity</td><td>Increased</td></tr>
<tr><td>58 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451465324 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>SLCO1B1</td><td>rs4149056</td><td>CT</td><td>lovastatin</td><td>1A</td><td>Toxicity</td><td>Increased</td></tr>
<tr><td>59 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447673005 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>VKORC1</td><td>rs9923231</td><td>CT</td><td>warfarin</td><td>1B</td><td>Toxicity</td><td>Increased</td></tr>
<tr><td>60 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451243676 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>VKORC1</td><td>rs9923231</td><td>CT</td><td>phenprocoumon</td><td>2A</td><td>Toxicity</td><td>Increased</td></tr>
<tr><td>61 <a href=https://www.pharmgkb.org/clinicalAnnotation/1448635217 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>NUDT15</td><td>*1</td><td>*1</td><td>mercaptopurine</td><td>1A</td><td>Dosage</td><td>Increased</td></tr>
<tr><td>62 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451251080 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP3A4</td><td>*1</td><td>*1</td><td>tacrolimus</td><td>2A</td><td>Dosage</td><td>Increased</td></tr>
<tr><td>63 <a href=https://www.pharmgkb.org/clinicalAnnotation/1449296086 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP3A4</td><td>*1</td><td>*1</td><td>fentanyl</td><td>2A</td><td>Dosage</td><td>Increased</td></tr>
<tr><td>64 <a href=https://www.pharmgkb.org/clinicalAnnotation/982035703 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>VKORC1</td><td>rs2884737</td><td>AC</td><td>warfarin</td><td>2A</td><td>Dosage</td><td>Increased</td></tr>
<tr><td>65 <a href=https://www.pharmgkb.org/clinicalAnnotation/655384733 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>VKORC1</td><td>rs7294</td><td>CT</td><td>warfarin</td><td>1B</td><td>Dosage</td><td>Increased</td></tr>
<tr><td>66 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451214480 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP3A5</td><td>*3</td><td>*3</td><td>tacrolimus</td><td>1A</td><td>Metabolism/PK</td><td>Decreased</td></tr>
<tr><td>67 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451241780 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP3A5</td><td>*3</td><td>*3</td><td>tacrolimus</td><td>1B</td><td>Metabolism/PK</td><td>Decreased</td></tr>
<tr><td>68 <a href=https://www.pharmgkb.org/clinicalAnnotation/1184999911 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP3A5</td><td>*3</td><td>*3</td><td>tacrolimus</td><td>1B</td><td>Metabolism/PK</td><td>Decreased</td></tr>
<tr><td>69 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451244700 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>SLCO1B1</td><td>rs4149056</td><td>CT</td><td>fluvastatin</td><td>1A</td><td>Metabolism/PK</td><td>Decreased</td></tr>
<tr><td>70 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451244800 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>SLCO1B1</td><td>rs4149056</td><td>CT</td><td>atorvastatin</td><td>1A</td><td>Metabolism/PK</td><td>Decreased</td></tr>
<tr><td>71 <a href=https://www.pharmgkb.org/clinicalAnnotation/1444686843 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP3A4</td><td>rs4646437</td><td>GG</td><td>tacrolimus</td><td>2A</td><td>Metabolism/PK</td><td>Decreased</td></tr>
<tr><td>72 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183680546 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs12979860</td><td>CT</td><td>boceprevir</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>73 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183680546 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs12979860</td><td>CT</td><td>peginterferon alfa-2a</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>74 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183680546 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs12979860</td><td>CT</td><td>peginterferon alfa-2b</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>75 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183680546 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs12979860</td><td>CT</td><td>ribavirin</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>76 <a href=https://www.pharmgkb.org/clinicalAnnotation/1154221922 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>ABCG2</td><td>rs2231142</td><td>GG</td><td>rosuvastatin</td><td>2A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>77 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183888969 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs12979860</td><td>CT</td><td>peginterferon alfa-2a</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>78 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183888969 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs12979860</td><td>CT</td><td>peginterferon alfa-2b</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>79 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183888969 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs12979860</td><td>CT</td><td>ribavirin</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>80 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183888969 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs12979860</td><td>CT</td><td>telaprevir</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>81 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447672998 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>VKORC1</td><td>rs9923231</td><td>CT</td><td>warfarin</td><td>2A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>82 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447673015 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>VKORC1</td><td>rs9923231</td><td>CT</td><td>warfarin</td><td>2A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>83 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447672600 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C9</td><td>*1</td><td>*1</td><td>warfarin</td><td>2A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>84 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183680546 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs12979860</td><td>CT</td><td>boceprevir</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>85 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183680546 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL4</td><td>rs12979860</td><td>CT</td><td>boceprevir</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>86 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183680546 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs12979860</td><td>CT</td><td>peginterferon alfa-2a</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>87 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183680546 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL4</td><td>rs12979860</td><td>CT</td><td>peginterferon alfa-2a</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>88 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183680546 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs12979860</td><td>CT</td><td>peginterferon alfa-2b</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>89 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183680546 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL4</td><td>rs12979860</td><td>CT</td><td>peginterferon alfa-2b</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>90 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183680546 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs12979860</td><td>CT</td><td>ribavirin</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>91 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183680546 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL4</td><td>rs12979860</td><td>CT</td><td>ribavirin</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>92 <a href=https://www.pharmgkb.org/clinicalAnnotation/981239773 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs8099917</td><td>GT</td><td>interferons</td><td>1B</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>93 <a href=https://www.pharmgkb.org/clinicalAnnotation/981239773 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs8099917</td><td>GT</td><td>peginterferon alfa-2a</td><td>1B</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>94 <a href=https://www.pharmgkb.org/clinicalAnnotation/981239773 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs8099917</td><td>GT</td><td>peginterferon alfa-2b</td><td>1B</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>95 <a href=https://www.pharmgkb.org/clinicalAnnotation/981239773 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs8099917</td><td>GT</td><td>ribavirin</td><td>1B</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>96 <a href=https://www.pharmgkb.org/clinicalAnnotation/655386657 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>XRCC1</td><td>rs25487</td><td>CT</td><td>Platinum compounds</td><td>2B</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>97 <a href=https://www.pharmgkb.org/clinicalAnnotation/981202609 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>ATIC</td><td>rs4673993</td><td>CT</td><td>methotrexate</td><td>2B</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>98 <a href=https://www.pharmgkb.org/clinicalAnnotation/981475450 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>EGFR</td><td>rs121434569</td><td>CC</td><td>erlotinib</td><td>2B</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>99 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183888959 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs8099917</td><td>GT</td><td>peginterferon alfa-2a</td><td>2A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>100 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183888959 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs8099917</td><td>GT</td><td>peginterferon alfa-2b</td><td>2A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>101 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183888959 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs8099917</td><td>GT</td><td>ribavirin</td><td>2A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>102 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183888959 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs8099917</td><td>GT</td><td>telaprevir</td><td>2A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>103 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183888969 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs12979860</td><td>CT</td><td>peginterferon alfa-2a</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>104 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183888969 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL4</td><td>rs12979860</td><td>CT</td><td>peginterferon alfa-2a</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>105 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183888969 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs12979860</td><td>CT</td><td>peginterferon alfa-2b</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>106 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183888969 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL4</td><td>rs12979860</td><td>CT</td><td>peginterferon alfa-2b</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>107 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183888969 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs12979860</td><td>CT</td><td>ribavirin</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>108 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183888969 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL4</td><td>rs12979860</td><td>CT</td><td>ribavirin</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>109 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183888969 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs12979860</td><td>CT</td><td>telaprevir</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>110 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183888969 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL4</td><td>rs12979860</td><td>CT</td><td>telaprevir</td><td>1A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>111 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447672998 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>VKORC1</td><td>rs9923231</td><td>CT</td><td>warfarin</td><td>2A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>112 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447673015 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>VKORC1</td><td>rs9923231</td><td>CT</td><td>warfarin</td><td>2A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>113 <a href=https://www.pharmgkb.org/clinicalAnnotation/1448102439 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs11881222</td><td>AG</td><td>peginterferon alfa-2a</td><td>2A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>114 <a href=https://www.pharmgkb.org/clinicalAnnotation/1448102439 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs11881222</td><td>AG</td><td>peginterferon alfa-2b</td><td>2A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>115 <a href=https://www.pharmgkb.org/clinicalAnnotation/1448102439 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs11881222</td><td>AG</td><td>ribavirin</td><td>2A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>116 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451245360 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>SLC19A1</td><td>rs1051266</td><td>CT</td><td>methotrexate</td><td>2A</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>117 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451250540 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>EGFR</td><td>rs121434569</td><td>CC</td><td>gefitinib</td><td>2B</td><td>Efficacy</td><td>Decreased</td></tr>
<tr><td>118 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183621000 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>G6PD</td><td>B (wildtype)</td><td>B (wildtype)</td><td>rasburicase</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>119 <a href=https://www.pharmgkb.org/clinicalAnnotation/1449188570 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C9</td><td>*1</td><td>*1</td><td>acenocoumarol</td><td>1B</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>120 <a href=https://www.pharmgkb.org/clinicalAnnotation/1449269868 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C9</td><td>*1</td><td>*1</td><td>acenocoumarol</td><td>2A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>121 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451448820 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>NUDT15</td><td>*1</td><td>*1</td><td>mercaptopurine</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>122 <a href=https://www.pharmgkb.org/clinicalAnnotation/1184648909 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>TPMT</td><td>*1</td><td>*1</td><td>mercaptopurine</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>123 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451678600 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C9</td><td>*1</td><td>*1</td><td>fluvastatin</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>124 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447672658 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C9</td><td>*1</td><td>*1</td><td>warfarin</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>125 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447672988 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C9</td><td>*1</td><td>*1</td><td>warfarin</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>126 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451237240 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>TPMT</td><td>*1</td><td>*1</td><td>azathioprine</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>127 <a href=https://www.pharmgkb.org/clinicalAnnotation/981203618 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>DPYD</td><td>rs67376798</td><td>TT</td><td>fluorouracil</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>128 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451263877 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CACNA1S</td><td>rs1800559</td><td>CC</td><td>enflurane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>129 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451263966 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CACNA1S</td><td>rs1800559</td><td>CC</td><td>methoxyflurane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>130 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451263973 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CACNA1S</td><td>rs1800559</td><td>CC</td><td>sevoflurane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>131 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451263980 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CACNA1S</td><td>rs1800559</td><td>CC</td><td>halothane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>132 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451263986 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CACNA1S</td><td>rs1800559</td><td>CC</td><td>isoflurane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>133 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451264020 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CACNA1S</td><td>rs1800559</td><td>CC</td><td>succinylcholine</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>134 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451274090 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>DPYD</td><td>rs67376798</td><td>TT</td><td>capecitabine</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>135 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183705783 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>RYR1</td><td>rs118192167</td><td>AA</td><td>desflurane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>136 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183705783 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>RYR1</td><td>rs118192167</td><td>AA</td><td>enflurane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>137 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183705783 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>RYR1</td><td>rs118192167</td><td>AA</td><td>halothane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>138 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183705783 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>RYR1</td><td>rs118192167</td><td>AA</td><td>isoflurane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>139 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183705783 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>RYR1</td><td>rs118192167</td><td>AA</td><td>methoxyflurane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>140 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183705783 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>RYR1</td><td>rs118192167</td><td>AA</td><td>sevoflurane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>141 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183705783 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>RYR1</td><td>rs118192167</td><td>AA</td><td>succinylcholine</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>142 <a href=https://www.pharmgkb.org/clinicalAnnotation/1445401008 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CACNA1S</td><td>rs1800559</td><td>CC</td><td>desflurane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>143 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447673759 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>RYR1</td><td>rs118192178</td><td>CC</td><td>desflurane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>144 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447673759 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>RYR1</td><td>rs118192178</td><td>CC</td><td>enflurane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>145 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447673759 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>RYR1</td><td>rs118192178</td><td>CC</td><td>halothane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>146 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447673759 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>RYR1</td><td>rs118192178</td><td>CC</td><td>isoflurane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>147 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447673759 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>RYR1</td><td>rs118192178</td><td>CC</td><td>methoxyflurane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>148 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447673759 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>RYR1</td><td>rs118192178</td><td>CC</td><td>sevoflurane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>149 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447673759 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>RYR1</td><td>rs118192178</td><td>CC</td><td>succinylcholine</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>150 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447673778 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>RYR1</td><td>rs193922818</td><td>GG</td><td>desflurane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>151 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447673778 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>RYR1</td><td>rs193922818</td><td>GG</td><td>enflurane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>152 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447673778 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>RYR1</td><td>rs193922818</td><td>GG</td><td>halothane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>153 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447673778 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>RYR1</td><td>rs193922818</td><td>GG</td><td>isoflurane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>154 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447673778 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>RYR1</td><td>rs193922818</td><td>GG</td><td>methoxyflurane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>155 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447673778 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>RYR1</td><td>rs193922818</td><td>GG</td><td>sevoflurane</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>156 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447673778 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>RYR1</td><td>rs193922818</td><td>GG</td><td>succinylcholine</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>157 <a href=https://www.pharmgkb.org/clinicalAnnotation/982030836 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>UGT1A1</td><td>rs10929302</td><td>AG</td><td>irinotecan</td><td>2A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>158 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451266120 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>DPYD</td><td>rs67376798</td><td>TT</td><td>tegafur</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>159 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451289660 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>DPYD</td><td>rs59086055</td><td>GG</td><td>fluorouracil</td><td>1A</td><td>Toxicity</td><td>Decreased</td></tr>
<tr><td>160 <a href=https://www.pharmgkb.org/clinicalAnnotation/982033279 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C9</td><td>*1</td><td>*1</td><td>acenocoumarol</td><td>1B</td><td>Dosage</td><td>Decreased</td></tr>
<tr><td>161 <a href=https://www.pharmgkb.org/clinicalAnnotation/655385012 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>VKORC1</td><td>rs9923231</td><td>CT</td><td>warfarin</td><td>1A</td><td>Dosage</td><td>Decreased</td></tr>
<tr><td>162 <a href=https://www.pharmgkb.org/clinicalAnnotation/981204044 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>VKORC1</td><td>rs9923231</td><td>CT</td><td>acenocoumarol</td><td>1A</td><td>Dosage</td><td>Decreased</td></tr>
<tr><td>163 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451241700 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP3A5</td><td>*3</td><td>*3</td><td>tacrolimus</td><td>2A</td><td>Dosage</td><td>Decreased</td></tr>
<tr><td>164 <a href=https://www.pharmgkb.org/clinicalAnnotation/981203719 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP3A5</td><td>*3</td><td>*3</td><td>tacrolimus</td><td>1A</td><td>Dosage</td><td>Decreased</td></tr>
<tr><td>165 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451243216 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP3A5</td><td>*3</td><td>*3</td><td>tacrolimus</td><td>2A</td><td>Dosage</td><td>Decreased</td></tr>
<tr><td>166 <a href=https://www.pharmgkb.org/clinicalAnnotation/981238341 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C9</td><td>*1</td><td>*1</td><td>warfarin</td><td>1A</td><td>Dosage</td><td>Decreased</td></tr>
<tr><td>167 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451237940 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>VKORC1</td><td>rs9923231</td><td>CT</td><td>phenprocoumon</td><td>1A</td><td>Dosage</td><td>Decreased</td></tr>
<tr><td>168 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451237200 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>TPMT</td><td>*1</td><td>*1</td><td>mercaptopurine</td><td>1A</td><td>Dosage</td><td>Decreased</td></tr>
<tr><td>169 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451237326 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>TPMT</td><td>*1</td><td>*1</td><td>azathioprine</td><td>1A</td><td>Dosage</td><td>Decreased</td></tr>
<tr><td>170 <a href=https://www.pharmgkb.org/clinicalAnnotation/982030369 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>-</td><td>rs12777823</td><td>AA</td><td>warfarin</td><td>1A</td><td>Dosage</td><td>Decreased</td></tr>
<tr><td>171 <a href=https://www.pharmgkb.org/clinicalAnnotation/655385392 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>VKORC1</td><td>rs9934438</td><td>AG</td><td>warfarin</td><td>1B</td><td>Dosage</td><td>Decreased</td></tr>
<tr><td>172 <a href=https://www.pharmgkb.org/clinicalAnnotation/655385028 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>VKORC1</td><td>rs8050894</td><td>CG</td><td>warfarin</td><td>1B</td><td>Dosage</td><td>Decreased</td></tr>
<tr><td>173 <a href=https://www.pharmgkb.org/clinicalAnnotation/655385012 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>VKORC1</td><td>rs9923231</td><td>CT</td><td>warfarin</td><td>1A</td><td>Dosage</td><td>Decreased</td></tr>
<tr><td>174 <a href=https://www.pharmgkb.org/clinicalAnnotation/981204044 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>VKORC1</td><td>rs9923231</td><td>CT</td><td>acenocoumarol</td><td>1A</td><td>Dosage</td><td>Decreased</td></tr>
<tr><td>175 <a href=https://www.pharmgkb.org/clinicalAnnotation/613978931 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>SCN1A</td><td>rs3812718</td><td>CT</td><td>carbamazepine</td><td>2B</td><td>Dosage</td><td>Decreased</td></tr>
<tr><td>176 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183704228 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>VKORC1</td><td>rs9934438</td><td>AG</td><td>acenocoumarol</td><td>2A</td><td>Dosage</td><td>Decreased</td></tr>
<tr><td>177 <a href=https://www.pharmgkb.org/clinicalAnnotation/655385024 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>VKORC1</td><td>rs2359612</td><td>AG</td><td>warfarin</td><td>1B</td><td>Dosage</td><td>Decreased</td></tr>
<tr><td>178 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451237940 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>VKORC1</td><td>rs9923231</td><td>CT</td><td>phenprocoumon</td><td>1A</td><td>Dosage</td><td>Decreased</td></tr>
<tr><td>179 <a href=https://www.pharmgkb.org/clinicalAnnotation/1449556772 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>SLCO1B1</td><td>rs4149056</td><td>CT</td><td>simvastatin</td><td>1A</td><td>Metabolism/PK</td><td>Moderate</td></tr>
<tr><td>180 <a href=https://www.pharmgkb.org/clinicalAnnotation/1449556772 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>SLCO1B1</td><td>rs4149056</td><td>CT</td><td>simvastatin acid</td><td>1A</td><td>Metabolism/PK</td><td>Moderate</td></tr>
<tr><td>181 <a href=https://www.pharmgkb.org/clinicalAnnotation/827862764 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs12979860</td><td>CT</td><td>peginterferon alfa-2a</td><td>1A</td><td>Efficacy</td><td>Moderate</td></tr>
<tr><td>182 <a href=https://www.pharmgkb.org/clinicalAnnotation/827862764 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs12979860</td><td>CT</td><td>peginterferon alfa-2b</td><td>1A</td><td>Efficacy</td><td>Moderate</td></tr>
<tr><td>183 <a href=https://www.pharmgkb.org/clinicalAnnotation/827862764 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs12979860</td><td>CT</td><td>ribavirin</td><td>1A</td><td>Efficacy</td><td>Moderate</td></tr>
<tr><td>184 <a href=https://www.pharmgkb.org/clinicalAnnotation/827862764 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs12979860</td><td>CT</td><td>peginterferon alfa-2a</td><td>1A</td><td>Efficacy</td><td>Moderate</td></tr>
<tr><td>185 <a href=https://www.pharmgkb.org/clinicalAnnotation/827862764 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL4</td><td>rs12979860</td><td>CT</td><td>peginterferon alfa-2a</td><td>1A</td><td>Efficacy</td><td>Moderate</td></tr>
<tr><td>186 <a href=https://www.pharmgkb.org/clinicalAnnotation/827862764 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs12979860</td><td>CT</td><td>peginterferon alfa-2b</td><td>1A</td><td>Efficacy</td><td>Moderate</td></tr>
<tr><td>187 <a href=https://www.pharmgkb.org/clinicalAnnotation/827862764 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL4</td><td>rs12979860</td><td>CT</td><td>peginterferon alfa-2b</td><td>1A</td><td>Efficacy</td><td>Moderate</td></tr>
<tr><td>188 <a href=https://www.pharmgkb.org/clinicalAnnotation/827862764 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL3</td><td>rs12979860</td><td>CT</td><td>ribavirin</td><td>1A</td><td>Efficacy</td><td>Moderate</td></tr>
<tr><td>189 <a href=https://www.pharmgkb.org/clinicalAnnotation/827862764 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>IFNL4</td><td>rs12979860</td><td>CT</td><td>ribavirin</td><td>1A</td><td>Efficacy</td><td>Moderate</td></tr>
<tr><td>190 <a href=https://www.pharmgkb.org/clinicalAnnotation/1444608384 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>FCGR3A</td><td>rs396991</td><td>AC</td><td>rituximab</td><td>2B</td><td>Efficacy</td><td>Moderate</td></tr>
<tr><td>191 <a href=https://www.pharmgkb.org/clinicalAnnotation/981238501 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CYP2C9</td><td>*1</td><td>*1</td><td>phenytoin</td><td>1A</td><td>Toxicity</td><td>Moderate</td></tr>
<tr><td>192 <a href=https://www.pharmgkb.org/clinicalAnnotation/827848365 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>MTHFR</td><td>rs1801133</td><td>AG</td><td>methotrexate</td><td>2A</td><td>Toxicity</td><td>Moderate</td></tr>
<tr><td>193 <a href=https://www.pharmgkb.org/clinicalAnnotation/655385307 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>MTHFR</td><td>rs1801133</td><td>AG</td><td>methotrexate</td><td>2A</td><td>Toxicity</td><td>Moderate</td></tr>
<tr><td>194 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451244040 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>VKORC1</td><td>rs9934438</td><td>AG</td><td>phenprocoumon</td><td>2A</td><td>Dosage</td><td>Moderate</td></tr>
<tr><td>195 <a href=https://www.pharmgkb.org/clinicalAnnotation/1449191407 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CFTR</td><td>rs113993958</td><td>GG</td><td>ivacaftor</td><td>1A</td><td>Efficacy</td><td>Unknown</td></tr>
<tr><td>196 <a href=https://www.pharmgkb.org/clinicalAnnotation/1449191413 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CFTR</td><td>rs77834169</td><td>CC</td><td>ivacaftor</td><td>1A</td><td>Efficacy</td><td>Unknown</td></tr>
<tr><td>197 <a href=https://www.pharmgkb.org/clinicalAnnotation/1449191430 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CFTR</td><td>rs121908752</td><td>TT</td><td>ivacaftor</td><td>1A</td><td>Efficacy</td><td>Unknown</td></tr>
<tr><td>198 <a href=https://www.pharmgkb.org/clinicalAnnotation/1183960805 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CFTR</td><td>rs80282562</td><td>GG</td><td>ivacaftor</td><td>1A</td><td>Efficacy</td><td>Unknown</td></tr>
<tr><td>199 <a href=https://www.pharmgkb.org/clinicalAnnotation/1449191758 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>CFTR</td><td>rs75541969</td><td>GG</td><td>ivacaftor</td><td>1A</td><td>Efficacy</td><td>Unknown</td></tr>
<tr><td>200 <a href=https://www.pharmgkb.org/clinicalAnnotation/981201981 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>DPYD</td><td>rs1801265</td><td>AG</td><td>fluorouracil</td><td>1A</td><td>Toxicity</td><td>Normal</td></tr>
<tr><td>201 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451287240 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>DPYD</td><td>rs1801265</td><td>AG</td><td>capecitabine</td><td>1A</td><td>Toxicity</td><td>Normal</td></tr>
<tr><td>202 <a href=https://www.pharmgkb.org/clinicalAnnotation/1449575656 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>DPYD</td><td>rs59086055</td><td>GG</td><td>fluorouracil</td><td>1A</td><td>Other</td><td>Uncertain</td></tr>
<tr><td>203 <a href=https://www.pharmgkb.org/clinicalAnnotation/1451274045 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>DPYD</td><td>rs67376798</td><td>TT</td><td>fluorouracil</td><td>1A</td><td>Other</td><td>Uncertain</td></tr>
<tr><td>204 <a href=https://www.pharmgkb.org/clinicalAnnotation/1447989706 target="_blank" style="color: #ffb30e"><i class="fa-solid fa-up-right-from-square"></i></a></td><td>DPYD</td><td>rs1801266</td><td>GG</td><td>fluorouracil</td><td>1A</td><td>Other</td><td>Uncertain</td></tr>
</table>

    <h2 id="about"><b>About</b></h2>
    <p class="main_lead">
      The report incorporates analyses of peer-reviewed studies and other publicly available information identified by PAnno by State Key Laboratory of Genetic Engineering from the School of Life Sciences and Human Phenome Institute, Fudan University, Shanghai, China. These analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research.<br>
      <em>Note:</em> A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.<br>
      <em>No Guarantee of Clinical Benefit:</em> This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This report also makes no promises or guarantees that a drug with a potential lack of clinical benefit will provide no clinical benefit.<br>
      <em>Treatment Decisions are Responsibility of Physician:</em> Drugs referenced in this report may not be suitable for a particular patient. The selection of any, all, or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, following the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this test or the information contained in this report.<br>
      When using results obtained from PAnno, you agree to cite PAnno.
    </p>
    </div>

    <div class="footer">
      <p>
        <strong>
          <a href="https://github.com/PreMedKB/PAnno" target="_blank">PAnno v0.1.0</a>
        </strong>
        - Written by Yaqing Liu, et al.,
        available at <a href="https://github.com/PreMedKB/PAnno" target="_blank">GitHub</a>, 
        <a href="https://pypi.python.org/pypi/panno/" target="_blank">PyPI</a>, and <a href="http://anaconda.org/" target="_blank">Conda</a>.
        <br>
        Copyright &copy; 2021-2022 Center for Pharmacogenomics, Fudan University, China. All Rights Reserved.
      </p>
    </div>
    
    </body>
    </html>
    
